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AN OVERVIEW OF THE REGULATION AND
PATENTABILITY OF HUMAN CLONING AND
EMBRYONIC STEM CELL RESEARCH IN THE
UNITED STATES AND ANTI-CLONING
LEGISLATION IN SOUTH KOREA
Mikyung Kimt
I. INTRODUCTION
Scientists in South Korea have succeeded in obtaining
embryonic stem ("ES") cells from cloned human embryos.' A report
published by the journal Science describes the work, in which thirty
embryos, of about one hundred cells each, were created and used to
harvest ES cells that later differentiated into a variety of tissue types.2
While the findings offer hope for treating disease through so-called
therapeutic cloning, they have revived legal and ethical debates in the
United States.
In this work, a team of researchers led by Woo Suk Hwang of
Seoul National University collected two hundred forty oocytes4 from
sixteen unpaid volunteers, who knew their oocytes would be used for
scientific experiments. 5 The researchers transferred the nucleus of a
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1. See Sarah Graham, Cloned Human Embryos Yield Stem Cells, SCIENTIFIC
AMERICAN.COM, Feb. 13, 2004, at http://www.sciam.com/article.cftn?articlelD=OOOEOFIC-
EF9D-102B-AF9D83414B7F0000.
2. Id.; see also Woo Suk Hwang, et al., Evidence of a Pluripotent Human Embryonic
Stem Cell Line Derivedfrom a Cloned Blastocyst, 303 SCIENCE 1669, 1669-74 (2004).
3. See Graham, supra note 1.
4. An oocyte is a developing egg cell. DORLAND'S ILLUSTRATED MEDICAL DICTIONARY
1083 (24th ed. 1974).
5. See Hwang et al., supra note 2, at 1670. The researchers obtained approval for this
study from the Institutional Review Board on Human Subjects Research and Ethics Committee
(Hanyang University Hospital, Seoul, Korea).
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somatic cell6 into an oocyte, which had had its nucleus removed, from
the same donor.7 They used a slightly different technique to extract
the contents of the egg-a gentle extrusion technique8 instead of the
more commonly used suction technique 9-which, together with the
optimization of several critical steps, including careful timing and the
freshness of the donated eggs, may have aided their success.'0
Even with these improvements, the researchers could culture
only thirty hollow balls of cells called blastocysts, which yielded just
one ES cell line.'1 The resulting ES cells differentiated into three
tissue types. 12 Furthermore, when transplanted into mice, the cells
became more specialized, turning into cartilage, muscle, and bone.'
3
Recent developments in biotechnology confirm the rapid
advances in cloning research, exacerbating fears that the specter of
human clones looms in the near future. 14 If scientists continue to
overcome the technological difficulties, a legal regime that can
address human cloning issues may be the only means of controlling
the use of this revolutionary technology.
6. A somatic cell is a non-reproductive cell such as a cumulus cell (a follicular cell
surrounding the ovum in the side of a developing vesicular ovarian follicle). DORLAND'S
ILLUSTRATED MEDICAL DICTIONARY 1438 (24th ed. 1974).
7. See Hwang et al., supra note 2, at 1670. This is so-called somatic cell nuclear transfer
("SCNT"). In SCNT, the nucleus of an oocyte is removed and replaced by the nucleus from a
mature body cell, such as a skin cell or cumulus cell. See id
8. See Michael D. Lemonick, Cloning Gets Closer, TIME, Feb. 23, 2004, at 48, 50
(explaining that while most cloning researchers extract an egg's nucleus with a tiny pipette,
Moon and Hwang made a pinhole in the cell wall and used a tiny glass needle to apply pressure
and squeeze the nucleus out).
9. See Ian Wilmut, Cloning for Medicine, ISLAM SET, at
http://www.islamset.com/healnews/cloning/wilmut.html (last visited May 5, 2005).
10. See Graham, supra note 1. The list of successfully cloned animals includes sheep,
mice, horses and cats, among others, but primates have proved difficult. Id.; see also Hwang et
al., supra note 2, at 1670 (stating that they optimized several critical steps, including
reprogramming time, activation method, and in vitro culture conditions).
11. See Hwang et al., supra note 2, at 1670 (stating that a total of 30 SCNT-derived
blastocysts were cultured, 20 inner cell masses were isolated by immunosurgical removal of the
trophoblast, and one ES cell line (SCNT-hES-1) was derived).
12. See id. Clumps of ES cells were cultured in vitro in suspension to form embryoid
bodies. The resulting embryoid bodies were found to differentiate into a variety of cell types,
including derivatives of endoderm, mesoderm, and ectoderm.
13. See id. When undifferentiated SCNT-hES-I cells were injected into the testes of
severe combined immundeficient mice, teratomas were obtained six to seven weeks after
injection. The resulting teratomas contained tissue representative of all three germ layers.
Differentiated tissues include neuroepithelial rosset, pigmented retinal epithelium, smooth
muscle, bone, cartilage, connective tissues, and glandular epithelium. Id.
14. See Richard A. Merrill & Bryan J. Rose, FDA Regulation of Human Cloning:
Usurpation or Statesmanship? 15 HARV. J.L. & TECH. 85, 96 (2001).
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The scientific "society opposes reproductive cloning but strongly
supports studies related to stem cells."'15 The National Academy of
Sciences declared that therapeutic cloning has scientific potential and
should be allowed to continue under appropriate guidelines. 6 The
National Institutes of Health and forty Nobel Laureates also attest to
the value of this important research. 17 Professor Hwang, who led the
research, said, "Our inspiration is to treat incurable disease," and "[a]s
scientists, we think that this is our moral obligation [to treat incurable
disease]."'18 However, Professor Hwang's work has global political
implications, and legislators in many countries remain sharply divided
on how to regulate cloning advances or whether to permit them at
all.' 9 Cloning is not safe. For example, Dolly the sheep was the result
of two hundred and seventy-seven attempts to create a living clone.2°
Some believe that cloning treats human life like a commodity.21
Although it is broadly agreed upon that cloning should not be used to
reproduce humans, the technology's use in the laboratory for making
ES cells continues to provoke strong feelings on both sides of the
debate.22
Human cloning is explicitly banned in many countries, including
South Korea.23 Many regulatory positions distinguish between
creating a cloned embryo for reproductive purposes (reproductive
cloning) and for other purposes such as therapeutic or research
15. Antonio Regalado, Koreans Clone Human Embryo, Reap Stem Cells, WALL ST. J.,
Feb. 12, 2004, at B I (quoting Donald Kennedy, Editor-in-chief of Science). Experts say this is
the first bona fide publication disclosing how to clone human embryos. The technology,
sometimes called "therapeutic cloning," could open the door to custom-tailored transplant
treatments for such conditions as diabetes and spinal-cord injury. Id.
16. See 149 CONG. REC. H1397, H1398 (daily ed. Feb. 27, 2003) (statement of Rep.
McGovern).
17. See id.
18. See Regalado, supra note 15.
19. See id,
20. See 149 CONG. REC. H1397, H1399 (daily ed. Feb. 27, 2003) (statement of Rep.
Pitts).
21. Id.
22. See Regalado, supra note 15. Because of hopes it will lead to cures, patient groups
have rallied strongly behind the technique. Paralyzed actor Christopher Reeve called therapeutic
cloning his best chance for a cure, and had joined advocates in California who planned to
introduce a ballot measure to raise $3 billion from the state for such research. Critics oppose
therapeutic cloning both on religious grounds and out of concern that human embryos are
becoming an industrial commodity, created specifically for use in medical experimentation. Id.
23. See Shaun D. Pattinson & Timothy Caulfield, Variations and Voids: The Regulation
of Human Cloning around the World, BMC Medical Ethics, at
http://www.biomedcentral.com/1472-6939/5/9 (last visited Apr. 17, 2004); see also Lemonick,
supra note 8, at 49.
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cloning. 24 No jurisdiction has adopted legislation or guidelines
permitting reproductive cloning.25 However, with regard to the
banning of non-reproductive cloning, countries have taken different
positions. 26 According to a report, out of thirty countries studied,
seventeen prohibit non-reproductive cloning and thirteen permit it.
27
The regulatory approaches of countries that have adopted regulatory
measures on cloning vary greatly and the legal position in some
countries remains uncertain.28
The patentability of inventions created via human cloning and
stem cell research raises another issue, specifically the United States
Patent and Trademark Office's ("USPTO") human being exception.
Professor Hwang filed applications for patents based on the results of
his research2 9 In Professor Hwang's patents, he might have claimed a
pluripotent ES cell line ("SCNT-hES-1") from a cloned human
blastocyst; a method for establishing SCNT-hES-1; and/or specialized
cells subsequently developed from SCNT-hES-1 such as neuronal
cells. In the light of the human being exception under the current
USPTO policy, the availability of patent protection for such
inventions in the United States would eventually call for an answer to
the question of what is the definition of a human being.3°
This article will review human cloning and ES cell research, the
federal regulation of human cloning and ES cell research in the
United States in comparison to the anti-cloning legislation in South
Korea, and the availability of patent protection of the results derived
from human cloning and ES cell research in the United States will be
reviewed.
24. See Pattinson & Caulfield, supra note 23.
25. See id. There are essentially only two regulatory approaches to reproductive cloning:




29. See Claudia Dreifus, 2 Friends, 242 Eggs and a Breakthrough: A Conversation with
Woo Suk Hwang and Shin Yong Moon, N.Y. TIMES, Feb. 17, 2004, at F I (quoting Hwang, "We
have applied for a worldwide P.C.T. [Patent Cooperation Treaty] patent for the technique we
developed and also the cloned human embryo stem cells.").
30. See infra Part IV.A. I.b.
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II. HUMAN EMBRYONIC STEM CELL RESEARCH
A. Characteristics and Types of Stem Cells
Stem cells have three important characteristics that distinguish
them from other types of cells.31 All stem cells, regardless of their
source, are capable of dividing and renewing themselves for long
periods; are undifferentiated 32; and can give rise to specialized cell
types such as nerve, blood, or liver cells.33 Stem cells come in
different varieties, relating to when and where they are produced
during development, and how versatile they are in terms of
developmental capabilities. 34 In the three- to five-day-old cloned
embryo, called a blastocyst, a small group of about thirty cells, called
the inner cell mass, gives rise to the hundreds of ES cells, very special
cells which can transform into any type of tissue.35 In the developing
fetus, stem cells in developing tissues differentiate into multiple
specialized cell types that form the heart, lung, skin, and other tissues
to make up an adult organism. 36 An adult stem cell that is an
undifferentiated cell of unknown origin is found among differentiated
cells in a tissue or organ.37 An adult stem cell can renew itself, and
can differentiate to yield the major specialized cell types of the
particular tissue or organ.38 The primary physiological roles of adult
stem cells in a living organism are to maintain and repair the tissue in
which they are found.39 Scientists primarily work with ES cells and
31. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: STEM CELL
BASICS: II. WHAT ARE THE UNIQUE PROPERTIES OF ALL STEM CELLS?, at
http://stemcells.nih.gov/info/basics/basics2.asp (last visited Apr. 6, 2005) [hereinafter
NATIONAL INSTITUTES OF HEALTH II].
32. See id. (stating that undifferentiated means not having changed to become a
specialized cell type); see also DORLAND'S ILLUSTRATED MEDICAL DICTIONARY 1672 (24th ed.
1974) (stating that undifferentiated means absent of normal differentiation).
33. See NATIONAL INSTITUTES OF HEALTH I1, supra note 31.
34. See id.
35. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: STEM CELL
BASICS: III. WHAT ARE EMBRYONIC STEM CELLS?, at
http://stemcells.nih.gov/info/basics/basics3.asp (last visited Feb. 26, 2005) [hereinafter
NATIONAL INSTITUTES OF HEALTH III].
36. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: REPORT ON STEM
CELLS, APPENDIX A: EARLY DEVELOPMENT, at
http://stemcells.nih.gov/info/scireport/PDFs/appendixa.pdf (last modified Aug. 20, 2004).
37. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: STEM CELL
BASICS: IV. WHAT ARE ADULT STEM CELLS?, at http://stemcells.nih.gov/info/basics/basics4.asp
(last visited Feb. 26, 2005) [hereinafter NATIONAL INSTITUTES OF HEALTH IV].
38. See id.
39. Id.
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adult stem cells obtained from animals and humans.40 The relative
merits of using ES cells and adult stem cells for research are still a
subject of debate.4 '
B. Cloning Employing Human Somatic Cell Nuclear Transfer
(SCNT)
Human ES cell research can further be divided based on whether
human ES cells come from cloning employing human somatic cell
nuclear transfer ("SCNT") or from conventional in vitro fertilization.
SCNT is generally defined as transferring the nucleus of a human
somatic cell 42 into an oocyte from which the nucleus has been
removed or rendered inert 3 As mentioned earlier, the focus of the
debate over governmental regulation on human ES cell research in the
United States is whether ES cells come from cloning employing
SCNT or from conventional in vitro fertilization.
Human ES cell research using cells created by SCNT, can be
classified as reproductive cloning or therapeutic cloning.
4
Reproductive cloning is generally defined as the use of cloning
technology, for initiating a pregnancy, while therapeutic cloning is
defined as conducting research on pluripotent stem cells that are
derived from a cloned embryo.45 Therefore, both reproductive cloning
and therapeutic cloning involve creating human embryos, only for
different purposes-initiating a pregnancy by implanting a cloned
embryo rather than conducting research on cloned embryos to
develop cell-based therapies.
Any discussion about the propriety of cloning should identify
both the type of technique being contemplated and the ends to which
40. Id.; see NATIONAL INSTITUTES OF HEALTH II, supra note 31.
41. See Stuart H. Orkin & Sean J. Morrison, Biomedicine: Stem-Cell Competition, 418
NATURE 25, 25-27 (2002) (referencing two papers that look at the abilities of embryonic and
adult stem cells; one by Kim Jong-Hoon et al., infra note 63 and the other by Jiang Yuehua et
al., infra note 69).
42. A somatic cell is a body cell, as opposed to a germ cell, which is an egg [oocyte] or
sperm cell. See DORLAND'S ILLUSTRATED MEDICAL DICTIONARY 1083, 1438 (24th ed. 1974).
43. See Jose B. Cibelli, et al., The First Human Cloned Embryo,
SCIENTIFIC AMERICAN.COM, Nov. 24, 2001, at
http://www.sciam.com/print-version.cfin?articlelD=0008B8F9-AC62- I C75-
9B81809EC588EF2 1; see also Jana Brenning, Therapeutic Cloning: How It's Done, SCIENTIFIC
AMERICAN.CoM, Nov. 24, 2001, at
http://www.sciam.com/print-version.cfm?arficlelD=00016CF7-CE54-1CF4-
93F6809EC5880000.
44. See Cibelli et al., supra note 43.
45. See id
2005] U.S. & KOREAN HUMAN CLONING REGULATIONS 651
that technique is directed. 4 The term cloning encompasses a variety
of research techniques and cloning technologies can be used for other
purposes besides producing the genetic twin of a non-human
organism. 47 Many cloning techniques are already widely accepted for
both scientific and industrial purposes.4 8 Current debate over
governmental regulation is focused on the use of human therapeutic
cloning to create genetically identical ES cell lines using a patient's
own genetic material obtained using nuclear transfer for the purpose
of cell-based therapies.
C. The Scientific Importance of Stem Cell Research
Human cloning employing SCNT is scientifically important
because of the utility of human embryonic stem cells in research, and
perhaps, in patient treatment. Studies of human embryonic stem cells
are advancing knowledge about how an organism develops from a
single cell and how healthy cells replace damaged cells in adult
organisms. 49 These studies are also leading scientists to investigate
the possibility of cell-based therapies to treat disease, often referred to
as regenerative or reparative medicine.50  Many biologists are
interested in using cloning techniques to genetically match cells to
patients for rejection-free transplants and research.5'
Human ES cells and adult stem cells each have advantages and
disadvantages regarding their potential use for cell-based regenerative
therapies.52 ES cells derived from very early human embryos can
proliferate indefinitely in culture while retaining the potential to
differentiate into virtually any cell type when coaxed.53 Stem cells
collected from tissues of adults or older embryos are typically more
46. See Merrill & Rose, supra note 14, at 92.
47. See id. at 90-97. Cloning, which literally means to make a copy, is the asexual
reproduction of a precise genetic copy of a molecule, cell, tissue, plant, or animal. The word
"cloning" can be used as a generic term to describe several different techniques of cloning.
Molecular cloning refers to the copying of DNA fragments. For example, the human gene for
insulin has been cloned into bacteria to produce insulin for the treatment of diabetes. In addition,
human cells are routinely cloned to study cancer or genetic diseases. Id.
48. See id.
49. See NATIONAL INSTITUTES OF HEALTH 11, supra note 31.
50. See id.
51. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: STEM CELL
BASICS: V. WHAT ARE THE SIMILARITIES AND DIFFERENCES BETWEEN EMBRYONIC AND
ADULT STEM CELLS?, at http://stemcells.nih.gov/info/basics/basics5.asp (last visited Apr. 9,
2005) [hereinafter NATIONAL INSTITUTES OF HEALTH V].
52. See id.
53. See Orkin & Morrison, supra note 41, at 25.
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restricted in their developmental potential and ability to proliferate.5 4
These distinctive properties are important, as stem cell replacement
therapies need a large number of cells as well as different kinds of
cells in order to effectively treat different diseases.55
However, there are technical obstacles to the use of ES cells.
56
First, ES cells can only be obtained from very early embryos and,
although several cell lines have been made from the ES cells
obtained; they will not be immunologically compatible with most
people who require cell transplants.57 Thus, researchers need to derive
more ES cell lines unless they customize ES cells on an individual
patient basis using therapeutic cloning. 58  Second, after being
transplanted undifferentiated ES cells form teratomas, which contain
various tissue types. 59 In order to be used for a specific cell-based
therapy, ES cells must be reliably differentiated into the appropriate
cell type in culture before transplantation.60 Finally, it has not yet
been proved that specialized cells derived from cultured ES cells
actually function within tissues after transplantation.61 It is possible
that cells generated in vitro are not equivalent to those arising in
vivo.62  Cells generated in vitro lack the benefit of the extensive
cellular interactions and education that take place during in vivo
development.
63
One potential advantage of using adult stem cells is that a
patient's own cells could be multiplied in culture and reintroduced
into the patient without being rejected by the immune system. 64 This
represents a significant advantage, as immune rejection is a major
problem that can only be circumvented with immunosuppressive
54. See id. For example, hematopoietic stem cells make all types of blood cells in vivo,
but proliferate little in culture and have been though not to make cells of other tissues. Id.; see
also NATIONAL INSTITUTES OF HEALTH 11, supra note 31. Adult stem cells are rare in mature
tissues and methods for expanding their numbers in cell culture have not yet been worked out.
Id.
55. See NATIONAL INSTITUTES OF HEALTH III, supra note 35.
56. See Orkin & Morrison, supra note 41, at 25.
57. See id.
58. Id.
59. Id.; see Hwang et al., supra note 2, at 1671-72.
60. See generally Orkin & Morrison, supra note 41.
61. See id.
62. Orkin & Morrison, supra note 41, at 25.
63. Id.; see also Jong-Hoon Kim et al., Dopamine Neurons Derivedfrom Embryonic Stem
Cells Function in an Animal Model of Parkinson's Disease, 418 NATURE 50, 50-56 (2002)
(reporting that the research team has overcome this problem in its work on rats with symptoms
of human Parkinson's disease).
64. See NATIONAL INSTITUTES OF HEALTH V, supra note 51.
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drugs. 65 Another advantage of using adult stem cells is that certain
kinds of adult stem cells seem to have the ability to differentiate into a
number of different cell types, given the right conditions.66 For
example, neural stem cells seem to have a previously unsuspected
developmental flexibility.67 Adult stem cells in which differentiation
can be controlled in the laboratory, may become the basis of therapies
for many serious common diseases.68 Therefore, exploring the
possibility of using adult stem cells for cell-based therapies has
become a very active area of investigation by researchers.69
Human therapeutic cloning employing SCNT has raised the
possibility of generating potentially unlimited sources of
undifferentiated cells for use in research, with potential applications
in tissue repair and transplantation medicine.7 ° Particularly, after
directed cell differentiation, SCNT-derived ES cells carrying the
nuclear genome of the patient7' could be transplanted without
invoking immune reaction.72 Further, the pluripotency of ES cells has
the potential to accommodate the various needs of patients affected by
many devastating conditions including diabetes, osteoarthritis, and
Parkinson's disease.73
65. Id.; see NATIONAL INSTITUTES OF HEALTH IV, supra note 37 (noting that adult blood
forming stem cells from bone marrow have been used in transplants for thirty years).
66. See NATIONAL INSTITUTE OF HEALTH IV, supra note 37. Developments in research
on adult stem cells have led scientists to ask whether adult stem cells could be used for
transplants. In the 1960s, researchers discovered that the bone marrow contains at least two
kinds of stem cells: hematopoietic stem cells, which forms all the types of blood cells in the
body, and bone marrow stromal cells, which have potential to generate bone, cartilage, fat, and
fibrous connective tissue. Id.
67. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: REPORT ON STEM
CELLS, THE ADULT STEM CELL, at http://stemcells.nih.gov/info/scireport/chapter4.asp (last
modified Aug. 20, 2004). Scientists now agree that the adult brain does contain stem cells that
are able to generate the brain's three major cell types-astrocytes and oligodendrocytes, which
are non-neuronal cells, and neurons or nerve cells. Id.
68. See NATIONAL INSTITUTES OF HEALTH IV, supra note 37.
69. See, e.g., Yuehua Jiang et al., Pluripotency of Mesenchymal Stem Cells Derived from
Adult Marrow, 418 NATURE 41, 41-49 (2002).
70. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: STEM CELL
BASICS: VI. WHAT ARE THE POTENTIAL USES OF HUMAN STEM CELLS AND THE OBSTACLES
THAT MUST BE OVERCOME BEFORE THESE POTENTIAL USES WILL BE REALIZED?, at
http://stemcells.nih.gov/info/basics/basics6.asp (last visited Feb. 26, 2005) [hereinafter
NATIONAL INSTITUTES OF HEALTH VI].
71. See Cibelli et al., supra note 43; see also Brenning, supra note 43.
72. See Cibelli et al., supra note 43.
73. See NATIONAL INSTITUTES OF HEALTH VI, supra note 70.
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III. REGULATION OF HUMAN CLONING AND EMBRYONIC STEM CELL
RESEARCH
A. Federal Regulation of Human Cloning and ES Cell Research
in the United States
Currently, no United States laws or regulations prohibit all
cloning research.74 Cloning techniques remain legal in the United
States. 75 Congress has failed to enact anti-cloning legislation.
However, human cloning and ES cell research in the United States
have been severely limited. The federal government allows the use of
federal funds for work on embryonic stem cells, but only on cell lines
from sanctioned samples. 76 Those cells lines, far fewer than were
promised, have many limitations and may be unsuitable for future
therapeutic applications.7 7
1. Constitutional Basis for a Federal Government Ban on
Human Cloning
The federal government may justify regulation of human cloning
by linking such regulation to its spending power or its power to
regulate interstate commerce.7 8 First, a federal ban on human cloning
research using federal funds is a permissible exercise of federal
spending power.79  The federal government regulates a variety of
medical and scientific activities that are linked to government
funding.80 For example, as a condition of receiving Medicare funds,
the federal government has imposed regulations on health care
providers which prohibit certain forms of fraud and abuse. In
74. See JUDITH A. JOHNSON & ERIN WILLIAMS, CRS REPORTS FOR CONGRESS: HUMAN
CLONING, at CRS-3 (Aug. 17, 2004), available at http://hutchison.senate.gov/RL31358.pdf.
75. See Pattinson & Caulfield, supra note 23.
76. See Press Release, Office of the Press Secretary, Fact Sheet: Embryonic Stem Cell
Research (Aug. 9, 2001), at http://www.whitehouse.gov/news/releases/2001/08/20010809-
1.html.
77. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: INFORMATION ON
ELIGIBILITY CRITERIA FOR FEDERAL FUNDING OF RESEARCH ON HUMAN EMBRYONIC STEM
CELLS, at http://stemcells.nih.gov/registry/eligibilityCriteria.asp (last modified Aug. 11, 2004);
Alvin Powell, From the Laboratory to the Patient: Stem Cell Institute Will Call on Expertise
from around the University to Turn Research into Therapy, HARV. UNIV. GAZETTE, Apr. 22,
2004, at http://www.news.harvard.edu/gazette/2004/04.22.99-StemOver.html.
78. See Lori B. Andrews, Is There a Right to Clone? Constitutional Challenges to Bans
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conjunction with providing federal funds for scientific research,
scientists must abide by federal regulations governing research.
82
Therefore, the federal government may prohibit human cloning by
banning the use of government funds for any research related to
human cloning or by requiring researchers to avoid such activities as
a condition of receiving federal funds.
Additionally, under the Commerce Clause the federal
government may regulate private research, which is conducted with
non-governmental funds or at institutions that do not receive federal
funding.83 Pursuant to the commerce power, Congress may regulate
interstate commerce, i.e., the channels and instrumentalities of
interstate commerce.84 Congress is also empowered to regulate things
or persons in or using those channels or instrumentalities if the
regulated activities are economic activities that substantially affect
interstate commerce as defined under governing United States
Supreme Court cases.85
In United States v. Darby, the Supreme Court stated that the
power of Congress over interstate commerce "extends to those
activities intrastate which so affect interstate commerce or the
exercise of the power of Congress over it as to make regulation of
them appropriate means to the attainment of a legitimate end, the
exercise of the granted power of Congress to regulate interstate
commerce." 86 In Wickard v. Filburn, the Court ruled that Congress
may regulate wheat production even if homegrown wheat only
indirectly caused a substantial economic effect on interstate
commerce. 87 The Court sustained the Agricultural Adjustment Act
when private consumption of homegrown wheat could collectively
have a substantial effect on interstate commerce.
88
In Katzenbach v. McClung, the Court held that Congress may
regulate racial discrimination by a private restaurant that received
food from out-of-state suppliers. 89 The Court reasoned that while such
activity by one local restaurant might have very little impact on
interstate commerce, the aggregation of that restaurant and others
82. Id.
83. Id.
84. See Allan Ides, The Partial-Birth Abortion Ban Act of 2003 and the Commerce
Clause, 20 CONST. COMMENT. 441,443-44 (2003-04).
85. See id. at 444-45.
86. See United States v. Darby, 312 U.S. 100, 118(1941).
87. See Wickard v. Filburn, 317 U.S. 111, 125 (1942).
88. See id. at 127-29.
89. See Katzenbach v. McClung, 379 U.S. 294 (1964).
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similarly situated could have a substantial effect on interstate
commerce. 90 In Perez v. United States, the Court upheld the federal
regulation of "loan sharking," largely controlled by organized crime,
by deferring to Congress' determination that purely intrastate
extortionate credit transactions affect interstate commerce. 91
While the Court had maintained an expansive reading of the
Commerce Clause in deference to Congress in Darby, Wickard,
McClung, and Perez, the Court restricted the breadth of the Clause in
the more recent cases, holding that Congress exceeded its commerce
power by attempting to regulate matters that were non-economic and
that had at best an attenuated connection with interstate commerce.92
In United States v. Lopez93 and United States v. Morrison, 94 the Court
held that the Gun-Free School Zones Act of 1990 and 42 U.S.C.
§ 13981, which provided a federal civil remedy for the victims of
gender-motivated violence, respectively, exceeded the authority of
Congress to regulate commerce among the several states under the
Commerce Clause. The Court held that both possession of a gun in a
local school zone and gender-motivated crimes of violence are not an
economic activity that might, through repetition elsewhere,
substantially affect any sort of interstate commerce.95 Both the Act
and § 13981 contained no jurisdictional element insuring that the
firearm possession in question affected interstate commerce 96 or
establishing a federal cause of action that was in pursuance of
Congress' power to regulate interstate commerce. 97 In both cases, the
Court stated that the Constitution required a distinction between what
was truly national and what was truly local in recognition of general
state police power.98
With respect to whether the Tenth Amendment limits the
commerce power, in National League of Cities v. Usery, the Court
concluded that the Tenth Amendment placed a substantive restriction
on the commerce power.99 Under the notion of state sovereignty, the
Court found the federal regulations that impaired the states' authority
90. See id. at 300--01.
91. See Perez v. United States, 402 U.S. 146 (1971).
92. See Ides, supra note 84, at 445.
93. See United States v. Lopez, 514 U.S. 549 (1995).
94. See United States v. Morrison, 529 U.S. 598 (2000).
95. See Lopez, 514 U.S. at 561; Morrison, 529 U.S. at 613.
96. See Lopez, 514 U.S. at 561; Morrison, 529 U.S. at 613.
97. See Morrison, 529 U.S. at 611-12.
98. See Lopez, 514 U.S. at 557; Morrison, 529 U.S. at 617-18.
99. See Nat'l League of Cities v. Usery, 426 U.S. 833, 842 (1976).
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to govern in matters of traditional state concern were outside the
scope of the commerce power. 100 However, in Garcia v. San Antonio
Metropolitan Transit Authority, the Court found that the states'
involvement in federal decision-making gave them a remedy through
the political process, implying that if a statute contains the requisite
connection to interstate commerce, it is constitutional despite any
encroachment on areas of traditional state authority.'0 ' Still more
recently, in New York v. United States, the Court spoke of the Tenth
Amendment as a restriction on the federal government's enumerated
powers.1
0 2
From the analysis of the prior United States Supreme Court cases
regarding federal powers, whether any anti-human cloning bill would
be sustained under the Commerce Clause would depend upon whether
1) human cloning would involve the use of channels or
instrumentalities of interstate commerce, or 2) the cloning activities
would have a substantial relationship to interstate commerce. The
second category would depend upon whether a) the cloning activity
would be an economic activity that substantially affects interstate
commerce; and b) the regulation including a jurisdictional element
would require that the cloning activity be connected to interstate
commerce. The court would also consider whether the regulation of
the cloning would encroach on matters of traditional state concern.
According to Professor Lori B. Andrews, a close analysis of
United States Supreme Court cases regarding federal powers provides
justification for federal action in the area of human cloning. 103
Cloning can be considered a commercial activity or product like
medicine. 10 4 Cloning could have a substantial impact on interstate
commerce similar to the activities of health care providers such as
dentists. 0 5  When analogized to the cases challenging the
constitutionality of the Freedom of Access to Clinic Entrances Act,
10 6
cloning clinics as well as cloning facilities would encompass
activities that would substantially affect interstate commerce. 107 Any
business involved with cloning that hires employees and purchases
equipment from out of state and then brings them into the state where
100. See id. at 855.
101. See Garcia v. San Antonio Metro. Transit Auth., 469 U.S. 528, 554 (1985).
102. See New York v. United States, 505 U.S. 144, 155-57 (1992).
103. See Andrews, supra note 78, at 669-75.
104. See id. at 671-72.
105. Id. at 672-73.
106. 18 U.S.C. § 248 (1994).
107. Andrews, supra note 78, at 673-74.
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they are located is engaged in interstate commerce.'0 8 Additionally,
by sharing information and research findings in a national arena, and
traveling and attending national classes and conferences, cloning
activity may satisfy the "substantially affects" requirement.'
0 9
Professor Andrews differentiated the activity of cloning from the
activities at issue in Lopez."0  Unlike primary and secondary
education, cloning activity does not affect an area of historically
extensive state regulation; and cloning would be provided at a
national level rather than a local level by a limited number of facilities
around the country that draw personnel and patients from a national
market."' It was also noted that human research has primarily been
funded and regulated by the federal government; a few states have
regulated the conduct of human research." 2 At least ten states have
introduced bills to deal with the issue of cloning. 1 3 The importance
of providing a sufficient legislative history was also noted. A
sufficient legislative history is necessary to indicate how cloning
would affect interstate commerce, establish why cloning is of national
importance, and document state legislative actions specifically asking
for the federal government to intervene in this area.' 4
2. Federal Ban on Human Cloning Research
a. Rider to the Consolidated Appropriations Act
A rider has affected funding for the National Institutes of Health
("NIH"). "1 The rider prohibits the Department of Health and Human
Services ("HHS") from using appropriated funds for the creation of
human embryos for research purposes or for research in which human
embryos are destroyed.11 6 This rider has been attached to the Labor,
HHS and Education Appropriations Acts for the 1997 fiscal year
108. Id. at 674.
109. See id. at 674.
110. See id., supra note 78, at 674-75.
111. See id. at 675.
112. See id.; see also National Conference of State Legislature, State Human Cloning
Laws, available at http://www.ncsl.org/programs/health/genetics/rt-shcl.htm (last updated Mar.
12, 2004).
113. See Andrews, supra note 78, at 75; see also National Conference of State Legislature,
supra note 112. As of March 12, 2004, at least ten states have enacted anti-cloning statutes. Id.
114. See Andrews, supra note 78, at 675.
115. See JOHNSON & WILLIAMS, supra note 74, at CRS-5.
116. See id.
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through the 2004 fiscal year." 7 Current statutory language prohibits
HHS from using 2004 fiscal year appropriated funds for:
(1) the creation of a human embryo or embryos for research
purposes; or
(2) research in which a human embryo or embryos are destroyed,
discarded, or knowingly subjected to risk of injury or death greater
than that allowed for research on fetuses in utero under 45 CFR
46.208(a)(2) and section 498(b) of the Public Health Service Act
(42 U.S.C. 289g(b)).
(b) For purposes of this section, the term "human embryo or
embryos" includes any organism, not protected as a human subject
under 45 CFR 46... that is derived by fertilization,
parthenogenesis, cloning, or any other means from one or more
human gametes or human diploid cells." 
8
b. Moratorium by President Clinton
In response to the creation of Dolly the sheep"t9 and concerns
about the potential application of cloning humans, politicians around
the world proposed or implemented bans on human cloning. 20 In the
United States, President Bill Clinton instituted a moratorium on
federal funding for human cloning experiments.' 2' Clinton also urged
the private sector to adopt a voluntary ban on the cloning of human
117. Id. at CRS-5 n.15; see, e.g., Consolidated Appropriations Act of 2004, Pub. L. No.
108-199, § 510(a), 118 Stat 3,277 (2004).
118. See Consolidated Appropriations Act of 2004 § 510.
119. See Tim Beardsley, A Clone in Sheep's Clothing, SCIENTIFIC AMERICAN.COM, Mar.
3, 1997, at http://www.sciam.com/print-version.cnfm?articleID=0009B07D-BD40-1C59-
B882809EC588ED9F (discussing results of experiments reported in I. Wilmut, et al., Viable
Offspring Derived from Fetal and Adult Mammalian Cells, 385 NATURE 810, 810-13 (1997)).
Scientists in Scotland had used SCNT in 1996 to produce the first cloned adult mammal, Dolly,
the sheep. Scientists at the Roslin Institute in Edinburgh removed the nucleus from a sheep egg
and replaced it with the nucleus of a mammary gland cell from an adult sheep. The resulting
embryo was then transferred to the uterus of a surrogate sheep. A total of 277 such embryos
were transferred, but only one lamb was born. Analyses of Dolly's genetic material confirmed
that she was derived from the adult lamb's mammary cell. They reported their results in Nature.
Id.
120. See Pattinson & Caulfield, supra note 23.
121. See Clinton Bars Federal Funds for Human Cloning Research, CNN.coM, Mar, 4,
1997, at http://www.cnn.com/TECH/9703/04/clinton.cloning/; see also JOHNSON & WILLIAMS,
supra note 74, at CRS-5. One month after the Dolly announcement, on March 4, 1997, President
Clinton sent a memorandum to the heads of all executive departments and agencies making it
"absolutely clear that no federal funds will be used for human cloning." Id. This action extended
the congressional ban beyond HHS to all federally supported research. Id.,
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beings.' 22 The NIH Guidelines on Stem Cell Research, published by
the Clinton Administration in August 2000, would not fund research
in which: (1) human stem cells were used for reproductive cloning of
a human; (2) human stem cells were derived using SCNT; or, (3)
human stem cells that were derived using SCNT were utilized in a
research project. 123
c. Decision by President Bush
The August 9, 2001 Bush Administration policy decision on
stem cell research stated that federal funds would not be used for the
cloning of human embryos for any purpose.124 The President
announced that federal funds may be awarded for research on existing
stem cell lines that were derived: (1) with the informed consent of the
donors; (2) from excess embryos created solely for reproductive
purposes; and (3) without any financial inducements to the donors.' 25
In contrast, no federal funds would be used for: (1) the derivation or
use of stem cell lines derived from newly destroyed embryos; (2) the
creation of any human embryos for research purposes; or (3) the
cloning of human embryos for any purpose.
1 26
According to a NIH report, investigators from ten laboratories in
the United States, Australia, India, Israel, and Sweden had already
derived stem cells from seventy-one individual, genetically diverse
blastocysts before President Bush's announcement. 27 The NIH
reports approximates that sixteen existing stem cell lines from
genetically diverse populations around the world would satisfy the
Bush Administration's criteria and be available for federally-funded
research.128 It is debatable whether the existing cell lines can satisfy
all needs of scientists in terms of their availability and quality.
129
President Bush's decision in 2001 does not prohibit a private
122. See JOHNSON & WILLIAMS, supra note 74, at CRS-5.
123. See id.
124. Id. at CRS-5 to CRS-6.
125. See Press Release, Office of the Press Secretary, supra note 76.
126. See id.
127. See NATIONAL INSTITUTES OF HEALTH, STEM CELL INFORMATION: NIH's ROLE IN
FEDERAL POLICY, at http://stemcells.nih.gov/policy/NlHFedPolicy.asp (last modified Jun. 10,
2004).
128. See NATIONAL INSTITUTES OF HEALTH, supra note 77.




2005] U.S. & KOREAN'HUMAN CLONING REGULATIONS 661
company from conducting stem cell research if it uses its own
funds. 130
d. Legislative Activities
Eight federal cloning bills that would prohibit SCNT to create
human beings and which could be interpreted as banning any cloning
technique in which an embryo is used, were proposed between March
1997 and February 1998.131 Five of the proposed bills would ban both
private and federal funding for conducting or supporting human
cloning or human cloning research, while three of the proposed bills
would only ban the use of federal funding.
1 32,
Interest in the issue began almost immediately at the beginning
of the 107th Congress, with independent announcements by two
scientists and a religious cult leader that they were working on the
technology to clone humans. 133 In addition, the announcement by
Advanced Cell Technology, a biotechnology company, that it had
cloned the first human embryos, galvanized opposition to cloning
130. See Powell, supra note 77 (noting that Douglas Melton of Harvard University
announced he had created seventeen new ES cell lines with private funds in February 2004).
131. See Andrews, supra note 78, at 677-79 tbl. 1. The eight bills consisted of three House
bills, four Senate bills and one by President Clinton. Of the eight proposals, six could be read to
ban transferring DNA into nonhuman cells; one was to ban embryo splitting. Id.
132. See id. Five proposals would impose civil penalties while one would impose criminal
penalties. Two proposals would have a sunset clause. Four proposals would establish a review
body that reports to legislature. Id.
133. See Office of Legislative Policy and Analysis, 107th Congress, Legislative Updates:
Cloning, at http://olpa.od.nih.gov/legislation/l07/pendinglegislation/7cloning.asp (last visited
Apr. 19, 2005); see also Rick Weiss, A Crucial Human Cell Isolated, Multiplied, WASH. POST,
Nov. 6, 1998, at Al, available at
http://www.washingtonpost.com/wp-srv/national/cellI 10698.htm.
James A. Thomson, an embryologist at the University of Wisconsin, and his
colleagues describe their success in today's issue of the journal Science. John D.
Gearhart of the Johns Hopkins University School of Medicine in Baltimore led
the other effort, results of which will appear in the Nov. 10 issue of the
Proceedings of the National Academy of Sciences.
Id.; see also Reproductive Cloning: They Want to Make a Baby, SCIENTIFIC AMERICAN.COM,
Nov. 24, 2001, at http://www.sciam.com/printversion.cfm?articlelD=OOOCCD17-DB53-ICF4-
93F6809EC5880000. The Raelians, a religious group, formed a company called Clonaid. A
chemist of Clonaid told the National Academy meeting in August 2001 that Clonaid had
hundreds of women willing to contribute eggs for use in cloning. The chemist argued that
people should have the liberty to reproduce how they want, whether by combining their genetic
material with another person's through sex or in vitro fertilization or by using only their own
genetic material to create a clone. Id.
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technology and led to the House passage of a measure that would
criminalize both reproductive and therapeutic cloning.
134
During the 107th Congress, the debate centered on whether to
legislatively ban reproductive cloning alone, or both reproductive
cloning and therapeutic cloning. 135 The House of Representatives held
four hearings on this issue. 136 The House passed a broad ban on all
forms of human cloning, 137 but the Senate failed to act, leaving the
matter to the 108th Congress to resolve.
138
During the 108th Congress, Congress continued to study various
proposals for enacting a total ban of human cloning by exercising
federal spending power and the power to regulate interstate
commerce. The announcement by Clonaid led several members of
Congress to introduce cloning bills soon after the 108th Congress
convened. 39 Again, there was considerable disagreement regarding
therapeutic cloning. 140 The Weldon-Stupak bill (House Bill 534),
prohibiting both human reproductive and therapeutic cloning, passed
the House of Representatives.' 41 The House rejected a competing
proposal that would allow and encourage the creation of human
embryos by cloning and would ban the use of any such cloned
embryo to initiate a pregnancy.
142
134. See Office of Legislative Policy and Analysis, 107th Congress, Legislative Updates:
Cloning at http://olpa.od.nih.gov/legislation/107/pendinglegislation/7cloning.asp (last visited
Apr. 19, 2005); see also Cibelli et al., supra note 43; Gary Stix, What Clones?: Were Claims of
the First Human Embryo Premature?, SCIENTIFIC AMERICAN.COM, Dec. 24, 2001, at
http://www.sciam.com/article.cfm?articlelD=OOOC5BD8-EE3D- ICF4-
93F6809EC5880000&pageNumber-3&catlD=4.
135. See Office of Legislative Policy and Analysis, 107th Congress, Legislative Updates:





139. See Office of Legislative Policy and Analysis, 108th Congress, Legislative Updates:
Cloning, at http://olpa.od.nih.gov/legislation/108/pendinglegislation/cloningl.asp (last visited
Apr. 19, 2005). "On December 27, 2002, Clonaid, a company affiliated with the pro-cloning
Raelian movement, announced that they had succeeded in cloning the first human baby." Id.
140. Id.
141. Id. On February 27, 2003, the House of Representatives passed, by a 241 to 155 vote,
the Human Cloning Prohibition Act of 2003 (House Bill 534) sponsored by Congressmen Dave
Weldon (R-FI.). Id. This bill, backed by President Bush, would ban the creation of human
embryos by cloning. See Executive Office of the President, Office of Management and Budget,
Statement of Administration Policy: H.R. 534-Human Cloning Prohibition Act of 2003, Feb.
26, 2003, at http://www.whitehouse.gov/omb/legislative/sap/108-1/hr534sap-hr.pdf.
142. The House rejected (23 1votes to 174) a competing bill proposed by Congressmen Jim
Greenwood (R-Pa.) and Peter Deutsch (D-FI.) that would have allowed and encouraged the
creation of human embryos by cloning, while attempting to ban the use of any such cloned
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In the Senate, the policy supported by President Bush was
embodied in the Brownback-Landrieu bill (Senate Bill 245). 143 The
language of Senate Bill 245 was nearly the same as House Bill 534 in
that both banned the creation of and trafficking in cloned human
embryos.'" Both bills forbid the use of SCNT to clone human
embryos, and banned private as well as public research on cloned
human embryos. 145 The House bill, however, also banned importation
of "any product derived from" cloned human embryos, while the
Senate bill did not.1 46 Both the House and Senate bills provided for up
to ten years in prison or fines of up to $1 million for violations.'
47
Senate Bill 245, which had twenty-eight sponsors and cosponsors as
of January 29, 2003, had been referred to the Senate Committee on
Health, Education, Labor, and Pensions, which was chaired by
Senator Judd Gregg (R-NH), who was a cosponsor of the bill in the
107th Congress. 1
48
The competing Hatch-Feinstein bill (Senate Bill 303) is different
from Senate Bill 245 with respect to the definition of human cloning,
the scope of prohibition, and penalties for violations. 49 Senate Bill
303 would have allowed the use of SCNT to clone human embryos
while it would have banned implantation of a cloned human embryo
into a uterus or the functional equivalent of a uterus.' 50 It imposed a
embryo to "initiate a pregnancy." See Office of Legislative Policy and Analysis, 108th
Congress, Legislative Updates: Cloning, at
http://olpa.od.nih.gov/legislation/108/pendinglegislation/cloningl.asp (last visited Apr. 19,
2005); Office of Legislative Policy and Analysis, Bill Tracking: House Bills-il08th Congress,
H.R. 534-Human Cloning Prohibition Act of2003, at
http://olpa.od.nih.gov/tracking/house bills/sessionl/hr-534.asp (last visited Apr. 19, 2005).
Following the House's rejection of the Greenwood bill and its approval of the Weldon-Stupak
bill, the President said in a written statement:
Like most Americans, I believe human cloning is deeply troubling, and I strongly
support efforts by Congress to ban all human cloning. We must advance the
promise and cause of medical science, including through ethical stem cell
research, yet we must do so in ways that respect human dignity and help build a
culture of life. I urge the Senate to act quickly on legislation banning all human
cloning.
See Press Release, Office of the Press Secretary, Statement by the President (Feb. 27, 2003), at
http://www.whitehouse.gov/news/releases/2003/02/20030227-20.html.
143. See S. 245, 108th Cong. (2003).
144. See id.; see also H.R. 534, 108th Cong. (2003).
145. See S. 245, 108th Cong. § 2 (2003); see also H.R. 534, 108th Cong. § 2 (2003).
146. See S. 245, 108th Cong. § 2 (2003); see also H.R. 534, 108th Cong. § 2 (2003).
147. See S. 245, 108th Cong. § 2 (2003); see also H.R. 534, 108th Cong. § 2 (2003).
148. See 2003 Bill Tracking S. 245, 108th Cong. (2003).
149. See S. 303, 108th Cong. § 101 (2003).
150. See id.
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rule which prohibited the creation of a cloned human embryo, an
"unfertilized blastocyst," which had developed past fourteen days of
age. 15 Additionally, the rule prohibited any research on this cell mass
because, at fourteen days, cell differentiation had begun. 52 As of
February 5, 2003, the bill had ten co-sponsors.
53
Since the ban on human cloning has not been enacted, scientists
may continue their attempts to overcome technical obstacles and
create cloned human embryos for research purposes. However, the
bar on the use of federal funds for research involving ES cells permits
federally funded scientists to experiment only with stem cell lines
created before the August 2001 announcement, regardless of the
quality and availability of these stem cell lines.
54
The debates are still ongoing. On July 10, 2002, the President's
Council on Bioethics issued recommendations with respect to
cloning. 155 The President's Council was split in its recommendations
regarding therapeutic cloning while it was unanimous in
recommending a permanent ban on reproductive cloning. 156 Ten
members of the Council recommended a four-year moratorium on
therapeutic cloning, in order to allow time for further review and
"democratic deliberation" of the issue. 157 Seven members of the
Council were in favor of therapeutic cloning, as long as standards are
developed for the regulation of such research. 
58
In the meantime, Harvard University has launched a
multimillion-dollar center to grow and study human embryonic stem
cells. 159 The center is expected to be the largest privately funded
American stem-cell research project to date.' 60 In addition, top
scientists from the United States, South Korea, Australia, and Britain
151. Seeid.§201.
152. See id.
153. 2003 Bill Tracking S. 245, 108th Cong. (2003).
154. See Press Release, Office of the Press Secretary, supra note 76.
155. See THE PRESIDENT'S COUNCIL ON BIOETHICS, HUMAN CLONING AND HUMAN
DIGNITY: AN ETHICAL INQUIRY (July 2002), available at
http://www.bioethics.gov/reports/cloningreport/index.html.




159. See Powell, supra note 77.
160. See Harvard to Create Stem-Cell Institute, THE WASH. TIMES, Mar. 1, 2004,
available at http://washingtontimes.com/nationa/20040301-124438-3363r.htm.
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pressed the United Nations on June 1, 2004 not to ban stem cell
research as part of a global treaty banning human cloning.'61
e. Weldon Amendment Banning Patents on Human
Organisms
Congress has enacted a prohibition on the patenting of human
embryos. 162 The new law, known as the Weldon Amendment (House
Bill 534), went into effect on January 23, 2004.163 The ban was
sponsored by Congressman Dave Weldon (R-Fl.), who, along with
Senator Sam Brownback (R-Ks.), has led efforts to ban human
cloning in the United States. 164 It received strong support from the
House and Senate Republican leadership, and from the Bush
administration. 1
65
The amendment provides congressional support for the current
federal policy against patenting humans. 166 The House-approved
amendment reads, "None of the funds appropriated or otherwise made
available under this Act may be used to issue patents on claims
directed to or encompassing a human organism."'167 Based on the
statement that the amendment that mirrored "the current policy
concerning patenting humans" had "exactly the same scope as the
current USPTO policy," the amendment attempts to provide
congressional support so that federal courts will not invalidate the
USPTO policy as going beyond the policy of Congress. 168 While the
161. See Irwin Arieff, Scientists Press UN to Allow Stem Cell Research,
Religionhumanrights.com, June 1, 2004, available at
http://religionhumanrights.com/Ethics/Health/stem.un.treaty.jnl .4.htm.
162. See Consolidated Appropriations Act of 2004, Pub. L. No. 108-199, § 634, 118 Stat
3, 101 (2004); see also Congress Bans Patents on Human Embryos; NRLC-backed Weldon
Amendment Survives BIO Attacks, National Right to Life, Feb. 4, 2004, at
http://www.nrlc.org/KillingEmbryos/HumanPatenting/Weldonamendmentsurvives.html
[hereinafter National Right to Life].




167. See Consolidated Appropriations Act of 2004, § 634.
168. See 149 CONG. REC. H7274 (daily ed. July 22, 2003) (statement of Rep. Weldon); see
also 149 CONG. REC. E2234-35 (daily ed. Nov. 5, 2003) (statement of Rep. Weldon).
Current USTPO [sic] policy, then, is that any claim that can reasonably be
interpreted as "directed to" or "encompassing" a human being, and any claim
reaching beyond "nonhuman" organisms to cover human organisms (including
human embryos), must be rejected. My amendment simply restates this policy,
providing congressional support so that federal courts will not invalidate the
USPTO policy as going beyond the policy of Congress (as they invalidated the
earlier USPTO policy against patenting living organisms in general).
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amendment, which does not provide the definition of a human
organism, may raise the concern of any expansive reading of the
amendment, Congressman Weldon further clarified that the
amendment would affect patenting human organisms, human
embryos, human fetuses or human beings with no bearing on stem
cell research or patenting genes. 169
House Bill 534 would have an impact on private funding of
human cloning. 170  When considering an investment in a
technologically-based company, venture capitalists typically will
conduct an evaluation of a company's patent portfolio, the extent of
which will depend, in part, on the importance of the patent portfolio
to the company's business model.17 1 If the amendment will make it
more difficult for biotech firms to receive patents over the results of
human cloning and ES cell research, biotech companies may
experience more difficulties convincing venture capitalists to invest.
Due to the importance of private funding in many biotechnological
inventions,' 72 House Bill 534 may have a significant impact on
biotech companies' ongoing attempts to create human embryos
through cloning. 1
73
Still, it is uncertain whether the amendment will change how the
courts will rule. Currently, courts would refuse to construe the
Id.
169. See Biotechnology Industry Organization, Cloning Patent Fact Sheet: New Patent
Legislation Sets Dangerous Precedent and Stifles Research, Sept. 2, 2003, at
http://www.bio.org/ip/action/cloningfactsheet.asp; see also 149 CONG. REC. E2417 (daily ed.
Nov. 22, 2003) (statement of Rep. Weldon).
What I want to point out is that the U.S. Patent Office has already issued patents
on genes, stem cells, animals with human genes, and a host of non-biologic
products used by humans, but it has not issued patents on claims directed to
human organisms, including human embryos and fetuses. My amendment would
not affect the former, but would simply affirm the latter.
Id.
170. See JOHNSON & WILLIAMS, supra note 74, at CRS-8. "This restriction could
potentially deter human embryo research and stem cell research because researchers might not
be able to claim ownership of their work." Id.
171. See William J. Fisher & Christopher J. Vemi, United States: What Venture
Capitalists Expect from Your Company's Intellectual Property, at
http://www.buildingipvalue.com/nus/97_101.htm (last visited Feb. 7, 2005).
172. See Rebecca S. Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 737-
38 (1990). The amount of federal funding (in the range of $200 million per year) for the Human
Genome Project is trivial compared to the amount of private funding for biotechnology research
and development ($1.5 to $2 billion in 1987). Id.
173. See id. Assuming that continued private funding is contingent on the availability of
patent protection, it is doubtful that federal funding for the Human Genome Project could
compensate for the reduction in private incentives for research and development if patent
protection were denied. Id.
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language of the amendment as a total ban on broadly defined human
cloning. For example, the courts may strike down the claim that
dopamine neuron cells purified from stem cell lines derived from a
cloned human embryo that did not develop a primitive streak are
directed to or encompassing a human being. Further, the legislative
history seems to support the position that the ban is meant to codify
the USPTO's existing ban on the claims directed to humans even
though courts do not necessarily look to the legislative history in
interpreting statutes, and do not always consider it dispositive.
17 4
3. FDA Regulation of Human Cloning and Stem Cell
Research
a. FDA Assertion of Its Jurisdiction over Human
Cloning
The Food and Drug Administration ("FDA") began to assert its
jurisdiction over human cloning in 1998.175 Initially, the FDA's
Acting Commissioner declared that, through the Federal Food, Drug,
and Cosmetic Act ("FDCA"), the FDA has the authority to regulate
human cloning and is prepared to assert that authority.176 The Acting
Commissioner explained that human cloning presents, "'serious
health and safety issues' for [both] the fetus and mother."' 177 He also
stated that human cloning may be considered a form of cellular or
genetic therapy, which requires prior approval by FDA reviewers,
because it involves "more than minimal manipulation" of human
cells, and thus presents health and safety issues for the fetus and the
mother. 178
i. Imposing a Warning and a Moratorium to
Human-Cloning Researchers
The FDA's assertion of jurisdiction over human cloning
occurred in January 1998 in the context of a warning to a Chicago
physicist who wanted to clone a human. FDA investigators made
174. See 149 CONG. REC. E2417 (daily ed. Nov. 22, 2003), supra note 169; see also
Special Committee on the Weldon Amendment to H.R. 2799, the Appropriation Bill for the
Departments of Commerce, Justice, State and the Judiciary, at 3 (2003-2004), available at
http://www.abanet.org/intelprop/summer2004/spec-comm.pdf (last visited May 5, 2005).
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clear to Dr. Seed that Federal regulations require him to file for FDA
approval before making any efforts to clone and that receiving
permission to proceed is highly unlikely. 7 9 In October 1998, the
FDA's Associate Commissioner for Medical Affairs sent a letter to
several hundred institutional review boards ("IRBs") throughout the
nation. 80 The letter confirmed the FDA's jurisdiction over "clinical
research using cloning technology to create a human being" and
explained the FDA's regulatory process and the requirements that
must be met before any investigator may proceed with such a clinical
investigation. 181 The letter clarified the formal means by which the
FDA would exert authority, i.e., the investigational new drug ("IND")
process and suggested that the FDA was already equipped to assess
the research protocols that required agency approval. 8
2
The FDA's invocation of its IND regime had the effect of
imposing a moratorium on most domestic human cloning research
because investigators and their sponsors that would conduct the type
of experiments subject to the FDA's jurisdiction were placed at legal
risk if they failed to seek and secure agency approval. 183 Moreover,
the Associate Commissioner's letter made it clear that the FDA may
still reject any research proposal on the basis of "major unresolved
safety questions pertaining to the use of cloning technology,"
regardless of a local IRB's approval.
184
ii. Scientific Concerns about Public Health and
Safety
While there had been no evidence that any researcher sought
FDA or IRB approval for any cloning experiment following the letter,
179. See 144 CONG. REC. S531, S562 (daily ed. Feb. 10, 1998). A letter from Sharon
Smith Holston, Deputy Commissioner for External Affairs, FDA, to Senator Edward M.
Kennedy stated:
[The] FDA already has jurisdiction over such experiments and is prepared to
exercise that jurisdiction. While FDA's authority does not address the larger
question of whether or not creating a human being using cloning technology
should be altogether prohibited, this authority will ensure that such
experimentation does not proceed until basic questions about safety are
answered.
Id.
180. See Merrill & Rose, supra note 14, at 87.
181. See Letter from Dr. Stuart Nightingale, Associate Commissioner for Medical Affairs,
FDA, to institutional review boards (Oct. 26, 1998), at
http://www.fda.gov/oc/ohrt/irbs/irbletr.html.
182. See Merrill & Rose, supra note 14, at 102.
183. See id.; see also Weiss, supra note 175, at Al.
184. See Letter from Dr. Stuart Nightingale, supra note 181.
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and there were no reports of any INDs submitted for such
experiments, the FDA reiterated its claim to regulatory jurisdiction.185
More importantly, the Director of the FDA's Center for Biologics
Evaluation and Research clarified that the FDA's role and
responsibilities in regulating the use of cloning technology to clone a
human being will be based on the FDA's scientific concerns about
public health and safety.' 86 Therefore, the agency drew a distinction
between the moral or ethical concerns underpinning the Bush
administration's opposition to human cloning and the FDA's own
scientific concerns about safety.'
87
iii. Regulation under the FDCA and PHSA
The use of cloning technology, to clone a human being, and
create somatic cell therapy products would be subject to the biologics
provisions of the Public Health Service Act ("PHSA"),188 as well as
the drug and device provisions of the Food, Drug, and Cosmetic Act
("FDCA").189 In addition, any somatic cell therapy product and
clinical research using cloning technology to clone a human being
would also be subject to IND application requirements. 190
Specifically, since 1997 the FDA has proposed a more comprehensive
regulatory approach for cellular and tissue-based products that include
somatic cell therapy products.' 91 In 2001, the FDA issued a final rule
that establishes the regulatory approach for human cells, tissues, and
185. See Merrill & Rose, supra note 14, at 102-03. At a hearing convened by the
Oversight and Investigations Subcommittee of the House Committee on Energy and Commerce,
on March 28, 2001, the Director of the FDA's Center for Biologics Evaluation and Research
reiterated the FDA's claim to regulatory jurisdiction, and in the process to elaborate its legal
reasoning, in response to reports that a U.S. researcher and a compatriot in Italy were planning
to produce the first human clone. Id.
186. See Issues Raised by Human Cloning Research: Hearing Before the Subcomm. on
Oversight and Investigations of the House Comm. On Energy and Commerce, 107th Cong. 78-
81 (2001) [hereinafter Zoon] (statement of Dr. Kathryn C. Zoon, Director, Center for Biologic
Evaluation and Research, FDA), at www.fda.gov/ola/2001/humancloning.html (Mar. 28, 2001);
see also
Merrill & Rose, supra note 14, at 103.
187. See Merrill & Rose, supra note 14, at 103-04.
188. Public Health Service Act, 42 U.S.C. §§ 201-300 (2004).
189. Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-397 (2004); see Merrill & Rose,
supra note 14, at 104 (quoting the Director's statement).
190. Merrill & Rose, supra note 14, at 104.
191. See Proposed Approach to Regulation of Cellular and Tissue-Based Products;
Availability and Public Meeting, 62 Fed. Reg. 9721, 9722 (Mar. 4, 1997) (to be codified at 21
C.F.R. ch. I).
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cellular and tissue-based products; the rule requires registration and
listing.1
92
iv. IND Process Requirements
Invoking the FDCA and PHSA, if human cloning falls within
any of the biologics or drug, and device requirements, the FDA may
address basic questions of safety and ensure that any human cloning
experiment does not proceed until such questions are answered.
93
First, the FDA has the authority to require pre-market approval and/or
licensing based upon reasonable, clinical assurance of safety, and
efficacy. 194 Specifically, the FDA may obligate human cloning
experiments to comply with the rigorous IND requirements of
detailed clinical protocols, patient informed consent, safety reports,
extensive record keeping, and continuing supervision by an IRB.' 95
Second, the FDA may put a "clinical hold" on any product that is
subject to the IND process. 196 The FDA may indefinitely delay or
suspend a proposed clinical investigation if the FDA finds that
"human subjects are or would be exposed to an unreasonable and
significant risk of illness or injury."' 97 Even after the FDA initially
approves an IND for human cloning, it could later terminate the IND
based upon safety concerns.
198
If the FDA has authority, any scientist who conducts human
cloning research in the United States without obtaining or retaining
the FDA's approval risks civil monetary penalties and/or criminal
sanctions such as misdemeanor and felony charges for the violation of
various provisions of the PHSA and FDCA. 199
192. See Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment
Registration and Listing, 66 Fed. Reg. 5447 (Jan. 19, 2001) (to be codified at 21 C.F.R. pts. 207,
807, and 1271).
193. See Zoon, supra note 186.
194. See 21 U.S.C. § 355 (2004); see also 21 U.S.C. § 360c(a)(l)(C) (2004); 21 U.S.C.
§ 360(e) (2004); 42 U.S.C. § 262a (2004); FDA Biologics, 21 C.F.R. § 60 0 .3 (p)-(s) (2004).
195. See FDA Drugs for Human Use, 21 C.F.R. § 312.2(a) (2004); see also Elizabeth C.
Price, Does the FDA Have Authority to Regulate Human Cloning? 11 HARV. J.L. & TECH. 619,
620-21 (1998).
196. See Price, supra note 195, at 621.
197. 21 C.F.R. § 312.42(b)(i) (2004).
198. See FDA Drugs for Human Use, 21 C.F.R. § 312.44(b)(i) (2004).
199. See Price, supra note 195, at 621 n.16 (referring to 42 U.S.C. § 262(f) and (d)(2)(B),
and 21 U.S.C. § 303(a) and § 333(f)).
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b. Legal Basis for Regulation of Human Cloning by
FDA
The FDA possesses a Constitutional power to regulate the
marketing and distribution in interstate commerce of drugs, medical
devices and biological products.200 As the Director of the FDA's
Center for Biologics Evaluation and Research asserted, °1 the FDA's
authority to regulate the use of human cloning technology is
legitimate only if the use of the cloning technology and somatic cell
therapy products derived from the use are considered drugs202 or
medical devices under the FDCA,2 °3 or biological products under the
PHSA.2 °4 Additionally, the FDA would have the authority to regulate
clinical research using human cloning technology itself, only if the
200. See Merrill & Rose, supra note 14, at 106-08.
201. See Zoon, supra note 186.
202. See 21 U.S.C. § 321(g)(1)(B)-(D) (2004). Under the FDCA the definition of the term
"drug" includes:
(B) articles intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals; (C) articles (other than food)
intended to affect the structure or any function of the body of man or other
animals; and (D) articles intended for use as a component of any article...
Id.
203. See 21 U.S.C. § 321(h)(2)-(3) (2004) Under the FDCA, a "medical device" is defined
as:
[A]n instrument, apparatus, implement, machine, contrivance, implant, in vitro
reagent, or other similar or related article, including any component, part, or
accessory [that is:]
(2) intended for use in the diagnosis of disease or other conditions, or in the cure,
mitigation, treatment, or prevention of disease, in man or other animals, or
(3) intended to affect the structure or any function of the body of man or other
animals, and
which does not achieve its primary intended purposes through chemical action
within or on the body of man or other animals and which is not dependent upon
being metabolized for the achievement of its primary intended purposes.
Id.
204. See 42 U.S.C. § 262(i) (2004). Under the PHSA a biological product is defined as:
"[Any] virus, therapeutic serum, toxin, antitoxin,... or analogous product, or arsphenamine or
[its] derivative[s] ... (or any other trivalent organic arsenic compound), applicable to the
prevention, treatment, or cure of disease or condition of human beings." Id. Thus, the definition
of a biological product has two components: (1) it must be a "virus, therapeutic serum.., or
analogous product"; and (2) it must be "applicable to the prevention, treatment, or cure of
disease or condition of human beings." The relevant questions are much the same as in the drug
and medical device context: (1) is there an identifiable "product" involved in human cloning;
and (2) if so, is that product "applicable to the prevention, treatment or cure of a disease or
condition of human beings"? Id.
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research involves an article within the meaning of the FDCA, whose
commercial distribution the FDA can regulate.2 °5
i. FDA's Authority to Regulate the Use of
Human Cloning Technologies to Create
Cloned Embryos or Somatic Cell Therapy
Products
Whether a court would find a cloned embryo or any somatic cell
therapy product derived therefrom as a drug or medical device under
the FDCA, or a biological product under the PHSA depends upon
whether the court would find that a cloned embryo or somatic cell
therapy product from the embryo could properly be considered an
"article '2°6 or "implant" 20 7 within the meaning of the FDCA, or a
"product" 20 8 within the meaning of the PHSA.20 9 Because the court
would not absurdly give the FDA authority to regulate the formation
of human life by concluding that such product is an "an "article" or
"implant" within the meaning of the FDCA, or "product" within the
meaning of the PHSA, the court's reasoning would eventually depend
upon whether a cloned embryo or somatic cell therapy product could
be considered a human being.210 In determining whether the embryo
or any derivative product could be considered a human being, the
court might consider particular properties of a cloned embryo or any
derivative product from a cloned embryo. These properties may
include the developmental stage or degree of differentiation of the
embryo or its product, implantability of the embryo or its product, and
any non-natural properties of the embryo or the product that cannot be
found in human embryos created physiologically or, perhaps, in
human embryos created by in vitro fertilization.
If a court were to conclude that a cloned embryo or any product
therefrom is a human being, the court would not find the embryo or
205. See 21 U.S.C. § 321(g)(1) (2004).
206. See id. § 321(g)(1)(B)-(D).
207. See id. § 321(h)(2)-(3); Price, supra note 195, at 634. The medical device definitions
depend upon the preliminary identification of a relevant "article," just as the drug definitions do.
However, the term "article" in the medical device definition is illustrated with examples such as
an "instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other
similar or related article." 21 U.S.C. § 321(h) (2004). Assuming a court would be willing to
entertain the notion that an embryo is an "article," a cloned embryo and any somatic cell therapy
product could fall within the term "implant" among the examples of "articles" covered by the
medical device definition. Id.
208. See 42 U.S.C. § 262(i) (2004).
209. See generally Price, supra note 195.
210. Id.
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the product as an article or implant within the meaning of the FDCA,
or a product within the meaning of the PHSA. Such construction
would not be consistent with common sense, legislative intent,21  and
the FDA's historical failure to assert jurisdiction over embryos
created through in vitro fertilization. 212 Therefore, products derived
from reproductive cloning activity aimed at producing children would
not be classified as drugs or medical devices, and would not be
subject to any of the FDA's regulation.213
In contrast, if a court were to conclude that a cloned embryo or
any product therefrom is not a human being, then to be considered a
drug or a medical device under the FDCA, or a biological product
under the PHSA, the embryo or product must be intended to prevent,
diagnose, or treat human or animal diseases or injuries; or intended to
affect a human or animal body structurally or functionally.214
Therefore, products derived from therapeutic cloning activity would
properly be classified as drugs or medical devices and would be
subject to the FDA's pre-market approval.21 5
ii. Regulation of Clinical Research Employing
Human Cloning Technology
The sources of the FDA's possible authority to regulate clinical
research include (a) the power to regulate marketing new drugs and
the shipping of experimental drugs under the FDCA216; (b) its limited
power to regulate transplantable human tissues based on the risk of
transmission of communicable diseases under the PHSA217; (c) the
federal requirements for the recovery, processing, and distribution of
transplantable human tissues under the FDA "plan for cellular and
211. See Price, supra note 195, at 630.
212. See id. at 630-31.
213. See id. at 641.
214. See 21 U.S.C. § 321(g)(1)(B) (2004) ("intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease"); see also id. § 321(g)(1)(C) (2004) ("intended
to affect the structure or any function of the body of man or other animals"); 42 U.S.C. § 262(i)
(2004) ("applicable to the prevention, treatment or cure of a disease of condition"). A cloned
embryo or any product could be manipulated to develop into a specific cell, organ, or tissue that
may then be injected, infused, or implanted into an individual who needs it to compensate for
any functional or structural insufficiency or deficiency. For example, dopamine neurons derived
from ES cells can be grafted into the midbrain of the patient diagnosed with Parkinson's disease.
Alternatively, an embryo or somatic cell therapy product could be programmed to develop into a
specific organ or tissue for implantation or transplantation.
215. See Price, supra note 195, at 641.
216. See The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-397 (2004); see id.
§§ 321, 331, and 355.
217. See 42 U.S.C. § 264(a) (2004).
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tissue-based products" 218 ; (d) its power to regulate gene therapy
experiments that involve the administration of unapproved biological
drugs subject to the FDA's IND regulations219; and (e) the authority to
require advance approval of human cloning experiments which rely
upon the conclusion that such experiments involve the administration
of unapproved drugs.2
The FDA oversight is an important feature of the medical
research environment in the United States. The FDCA requires
affirmative FDA approval for the marketing of any new drug.221 The
statute also specifies that, before granting approval, the FDA should
obtain sufficient evidence of safety and efficacy based on the clinical
trials in human subjects.222 Experiments that require FDA approval to
market new medical products encompass a major part of the clinical
research conducted at medical centers and other health care
institutions in the United States.223 Moreover, the FDCA imposes
conditions, primarily designed to protect the trial subjects' safety and
autonomy, on a manufacturer who wants exemptions under the statute
to ship experimental drugs for the purpose of conducting
investigational studies that will become part of an application for
marketing approval.224 Thus, federal oversight of medical research
involving human subjects is widespread in the two circumstances that
involve new drugs and experimental drugs, which comprise the bulk
of, if not all, clinical research using reproductive cloning technology
in the United States. The FDA's jurisdiction depends on the purpose
of the research and on the substances or products to which research
subjects are exposed.225 Furthermore, the FDA only has the authority
to regulate human research involving articles whose commercial
distribution the FDA can regulate, based upon the FDA's power
under the Constitution's Commerce Clause. 226
The FDA establishes minimum requirements for the recovery,
processing, and distribution of transplantable cellular and tissue-based
218. See THE FOOD AND DRUG ADMINISTRATION, PROPOSED APPROACH TO REGULATION
OF CELLULAR AND TISSUE-BASED PRODUCTS (Feb. 28, 1997), available at
http://www.fda.gov/cber/gdlns/CELLTISSUE.txt.
219. See Zoon, supra note 186.
220. See Merrill & Rose, supra note 14, at 119-24.
221. See id. at 108.
222. Id. at 109.
223. Id. at 106-07.
224. Id. at 109.
225. Id. at 107.
226. See Merrill & Rose, supra note 14, at 107; see also 21 U.S.C. § 321(g)(1) (2004).
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products. 227 However, the plan does not impose any restrictions on the
clinical use of appropriately screened and tested tissue, nor does it
require tissue banks to demonstrate that their products are safe or
effective. 228 Thus, without amending the regulations the FDA could
not have required advance approval of clinical human cloning
experiments using cellular and tissue-based products even if such
material is defined as human tissue.
229
The FDA's regulations governing transplantable human tissues
under the PHSA would authorize the FDA to pursue a relatively
narrow goal, i.e., the prevention of transmission of infectious diseases
from the donor(s) of cellular material to a cloned embryo or its
mother.230 The regulations do not require researchers to notify the
FDA of, or to acquire its approval for, any clinical use of tissue.231
The FDA announced that it considers somatic cell therapy
products as both biological products and drugs.232 The FDA also
claimed that the statutory authority on which the FDA relies to
regulate gene therapy also supports its jurisdiction over clinical
cloning experiments. 233 However, the FDA's regulation of gene
therapy experiments is not based on an explicit legislative grant of
jurisdiction.234 Rather, jurisdiction rests on the premise that the
clinical administration of genetic material to humans requires
approval of an IND because it constitutes the administration of an
experimental drug.235 In reality, the FDA's regime over recombinant
DNA gene therapy experiments gave primary responsibility to the
Recombinant DNA Advisory Committee ("RAC"), an entity
established by the NIH.23 6 Therefore, the FDA's regulation of gene
therapy experiments may offer a precedent for its assertion of
jurisdiction over cloning research, but it does not provide an
227. See THE FOOD AND DRUG ADMINISTRATION, supra note 218. In response to the
emergence of AIDS and the technological advances within the biotechnology industry, the FDA
promulgated these new regulations. Id.
228. See Merrill & Rose, supra note 14, at 113.
229. Seeid. at ll3.
230. Id. at 110.
231. Id. at II1.
232. Id. at 117.
233. Id.
234. See Merrill & Rose, supra note 14, at 118.
235. Id.
236. Id. at 117-18. The RAC's expertise led to it taking responsibility for reviewing both
medical and non-medical issues raised by proposed experiments, with FDA concurrence. Id.
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independent legal basis for the positions announced by FDA
officials.
237
The FDA's authority to require advance approval of human
cloning experiments depends upon the conclusion that such
experiments involve the administration of unapproved drugs. 238 For
any clinical experiment to be subject to FDA authority under the
FDCA, the procedure must involve the introduction of an article into
a human subject, which must fit the definition of a drug or device
under the FDCA.2 39
As the previous analysis demonstrates, use of reproductive
cloning technology and the FDCA's drug definition does not
comfortably encompass all of the applications now awaiting
investigation.240 The statute would give the FDA authority to regulate
human cloning experiments when it is used for disease prevention or
treatment purposes, but not when used for human reproduction.24'
c. Pros and Cons of the FDA Regulation of Cloning
Research
i. Plausible Arguments for Giving the FDA a
Role in Overseeing Human Cloning
Research
(J)De Facto Regulatory Regime
The FDA's assertion of jurisdiction over human cloning creates
at least a de facto regulatory regime.242 In the absence of targeted
legislation, the FDA's program for regulating clinical studies of new
medicines may be an instrument that enables the federal government
to oversee research into human cloning and cloning-related
technologies.243 The implementation of the FDA's regulatory regime
may discourage human cloning experiments without the need for new
legislation until the safety concerns surrounding human cloning can
be addressed. 244 The FDA's assertion of jurisdiction ostensibly might
237. See id. at 118.
238. Id. at 119.
239. Id.
240. See Price, supra note 195, at 641.
241. See id.
242. See Merrill & Rose, supra note 14, at 88.
243. See id. at 88-89.
244. Id. at 133.
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provide control of this provocative technology until more finely
calibrated requirements can be developed.245
(2)Familiarity and Flexibility
The basic outlines of the FDA regulatory regime are familiar to
medical researchers, and the FDA requirements are already
operational.246 The FDA regime also allows for flexibility by
considering research proposals on an individual basis even though
researchers must follow the basic requirements prescribed by agency
regulations and supporting guidelines.
24 7
(3)Preferable Alternative to a Broad
Legislative Ban
The FDA regulation could avoid the chilling effect on ES cell
research that would result from a congressional ban on all kinds of
human cloning employing SCNT.248 Many professional and industry
groups expressed concern that a broad ban would disrupt or end
valuable ongoing genetic research.249 For them, latent FDA
jurisdiction offers an alternative to possible efforts to craft finely-
tuned controls through the legislative process.
2 50
Legislation to regulate human cloning is particularly challenging
to legislators. It has been difficult for advocates of legislation to agree
on what they want to restrict. 251 In addition, fashioning a finely-tuned
law in this complex area is not an easy task because technological
advances may circumvent carefully drawn laws.252 Any attempt to
address the problem legislatively must not only consider the effect a
ban would have on beneficial technologies, but must also take into
account future technological breakthroughs and new applications of
existing techniques.253 Finally, the nature of the cloning debate, which
heightens emotions and inhibits reflective deliberation, has resulted in
legislators hastily drafting bills that represent political statements of
moral outrage rather than vehicles for exploration and dialogue.254
245. Id. at 131.
246. Id.
247. id.
248. See Merrill & Rose, supra note 14, at 131-33.




253. Id. at 132-33.
254. See Merrill & Rose, supra note 14, at 133.
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ii. Questionable Institutional Capacity
(1) Scientific Issues
The argument for FDA jurisdiction is strongest when one
considers medical concerns raised by human cloning.255 Cloning
technology has been unreliable with high error rates.256 Risks of fetal
and neonatal death, severe birth or developmental defects, and the
dangers to surrogates pregnant with clones that include miscarriage
have been identified.257 For example, of the twenty-nine early
embryos created by SCNT and implanted into various ewes by Roslin
researchers, only one, Dolly, survived.2 58 Furthermore, there is little
information regarding the complete genetic makeup, possible latent
defects, or the survival and long-term health of clones like Dolly.
259
Such potential physical risks make some administrative oversight
260
reassuring.
Other issues are important as well. For example, FDA officials
have the experience to make judgments on primarily scientific
tasks.2 61 Also, the FDA's regulatory regime is structured to ensure the
safety of new medicines before they are administered to human
beings. 262 Finally, the FDA and the IRBs are generally capable of
addressing the safety of dramatic scientific advances and novel
medical applications.263
(2) Moral and Ethical Issues
It has been argued that an effective regime for regulating cloning
must be capable of assessing not only scientific issues, but also moral
and ethical issues.26 Cloning elicits unique moral and ethical issues
that any governmental authority must surely confront in regulating
255. See id. at 134.
256. Id.; see 149 CONG. REC. H1397, H1399 (daily ed. Feb. 27, 2003) (statement of Rep.
Pitts).
257. See Merrill & Rose, supra note 14, at 134.
258. See Ronald M. Green, I, Clone, SCIENTtFIC AMERiCAN.COM, Sept. 3, 1999, at
http://www.sciam.com/print-version.cfm?articleID=000329A6-CE72-1CFB-
93F6809EC5880000.
259. See Merrill & Rose, supra note 14, at 134.
260. See id. at 135.
261. Id.
262. Id. at 134.
263. Id.
264. Id. at 133.
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cloning research. 265 The ethical issues raised by the use of SCNT to
create children relate to serious safety concerns, individuality, family
integrity, and treatment of children as objects.266 There are concerns
about possible harms to children who may be born as a result of
SCNT.26 7  Possible harms include physical harms from the
manipulation of ova, nuclei, and embryos, which are integral to the
technology, and psychological harms, such as a diminished sense of
individuality and personal autonomy.2 68 Additionally, there are fears
that widespread practice of such cloning would undermine important
social values, such as opening the door to a form of eugenics,
tempting some people to manipulate others as if they were objects
instead of persons, and exceeding the moral boundaries inherent to
the human condition. 269 Whether administrative regulation is a
normatively attractive means to address the complex scientific, moral,
and ethical issues surrounding cloning, and whether the FDA has the
qualifications and resources necessary for the task are big
questions.27°
(3)Limitations of the FDA's IND Regime
It is uncertain whether the FDA is fully prepared to address the
271
risks presented by human cloning experiments. The FDA's IND
regime, which was designed long before cloning technologies were
realistic possibilities, will be applied to regulate human cloning
activities.272 The IND regime was initially designed for the purpose of
overseeing the clinical testing of new drugs.273 The primary goals of
section 505(i) of the FDCA'are to protect the safety and autonomy of
human subjects and to assure that the FDA has access to all evidence
relevant to assessing a drug's safety and efficacy.274 An IRB's
265. See Merrill & Rose, supra note 14, at 135-37. Concerns and issues that face
governments include the status of cloned humans as autonomous individuals, the psychological
burdens and identity distortions that cloning might entail, the concern for the protection of
individuality from a fundamental threat to the concept and the reality of the human being as a
unique and intrinsically valuable entity, and the debates over the moral status of clones. Id.
266. See NATIONAL BIOETHICS ADVISORY COMMISSION, CLONING HUMAN BEINGS: CH. 4




270. See Merrill & Rose, supra note 14, at 135-37.
271. Id. at 137.
272. Id. at 88.
273. Id. at 137-39.
274. Id. at 137-38.
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primary responsibility is to protect the safety and assure the informed
consent of study participants.275 Neither the FDA nor IRBs are
directed to assess whether a study is morally acceptable or socially
beneficial.276 The FDA has confined its own review to the immediate
27
safety of study participants.  Thus, rather than relying on established
procedures, the FDA needs to specifically fashion new rules to
encompass human cloning experiments.278
In summary, the FDA regulation over human cloning has
limitations.279 Regardless of these limitations, the FDA may still be
able to address foreseeable medical concerns related to therapeutic
cloning. 280 Additionally, it may be able to regulate procedures and
experiments, including clinical trials, related to therapeutic cloning
and any products resulting from therapeutic cloning. However, the
current FDA regulation cannot assess moral or ethical issues
regarding human cloning.28' Futhermore, it cannot regulate any
product, procedure or experiment related to reproductive cloning.282
B. Regulation of Human Cloning and Embryonic Stem Cell
Research in South Korea
The Bioethics and Biosafety Act was passed by the National
Assembly of South Korea on December 29, 2003.283 The process of
reaching a national consensus in order to pass the act took
approximately seven years and more than a dozen draft bills.284 Under
this act, human reproductive cloning and experiments, such as
interspecies nuclear fusion, are strictly banned in South Korea.285
275. Id. at 138.
276. See Merrill & Rose, supra note 14, at 138.
277. Id.
278. Id. at 133.
279. Id. at 135-39.
280. Id. at 134-35.
281. Id. at 135-37.
282. See Price, supra note 195, at 641.




284. See Han Sung-Goo, et al., New Cloning Technologies and Bioethics Issues: The
Legislative Process in Korea, 13 EUBIOS J. ASIAN & INT'L BIOETHICS 216-19 (2003), at
http://www.biol.tsukuba.ac.jp/-macer/EJ1 36/ejl 36h.htm (last visited Mar. 21, 2005).
285. See Joseph Wong, et al., South Korean Biotechnology-A Rising Industrial and
Scientific Powerhouse, 22 NATURE BIOTECHNOLOGY SUPPLEMENT DC42, DC46 (2004),
available at http://www.utoronto.ca/jcb/home/documents/SouthKorea.pdf.
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However, therapeutic cloning is permitted in limited cases for the
cure of otherwise untreatable diseases.
286
1. Legislative Progress
a. The Biotechnology Support Act of 1983 and Its
Amended Bills
The Biotechnology Support Act of 1983 ("1983 Act") was
enacted to promote the development of biotechnology.287 Article 15 of
the 1983 Act mandates that the Minister of Health and Welfare
prepare and implement guidelines on experiments.288 It lists actions
that should be taken in order to prevent ethical problems from arising,
such as the prohibition of human gene recombination and any other
experiments that may cause detrimental impacts to human dignity.289
In preparation for joining the Organization of Economic
Cooperation and Development and the International Convention on
Biological Diversity in 1997, the Korean government formulated
guidelines reiterating Article 15 of the 1983 Act.290 Until now, there
have been no regulatory provisions at the level of statutes,
regulations, or guidelines notified by the governmental agencies,
which address substantially bioethical concerns stemming from the
application of advanced biotechnology, such as artificial
286. See id.
287. See The Biotechnology Support Act, Art. 1 (1983) ("build up the foundation for
biotechnological research, and thereby to effectively foster and develop biotechnology and
promote the industrialization of such developed technology"); see also Han et al., supra note
284.
288. See The Enforcement Decree of the Biotechnology Support Act, Art. 15(1) (issued in
1984) ("[N]ecessary measures to prevent foreseeable biological hazards, negative effects on the
environment and ethical problems that may arise in the process of biotechnological research and
industrialization, and shall include safety standards for the transfer, handling, and use of
genetically converted biological organisms.").
289. See id. Art. 15(2).
290. See Un Jong Pak, Legislative Progress on Bioethics and Safety in Korea and
Suggestions for the Future (Jan. 5-7, 2004) (article for the Beijing International Conference on
Bioethics) (on file with the Santa Clara Computer & High Technology Law Journal).
Accordingly, "The Guidelines for Gene Recombination Experiment" were created in 1997. Id.
The Guidelines require "developing measures necessary for the prevention of ethical problems,
such as prohibition of gene recombination experiment or any other experiments that may cause
detrimental impact to human dignity." The Biotechnology Support Act, Art. 23 (1983).
However, the Guidelines are just reiterating the provision in the Enforcement Decree of the
Biotechnology Support Act, and thus, in effect cannot be deemed to contain a specific guidance
on ethics.
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insemination, human embryo research and handling, genetic testing,
gene therapy, protection of genetic information, and the gene bank. 291
Two amendment bills (Young-dal Chang on July 2, 1997; Sang-
hee Lee on November 19, 1998) were proposed at the 15th National
Assembly, as amendments to the Biotechnology Support Act in 1997
and in 1998, respectively, in order to cope with the ethical and safety
issues arising from the rapid development of biotechnology. 292 These
draft bills drew public attention and provoked discussions, including
several public hearings. Subsequently, another bill to prohibit human
cloning wai submitted in 1999, creating a deadlock situation of the
standing committees with no progress. 293 The third amendment bill
(Sung-jae Lee on November 5, 1999) purported to deter the negative
effects that may arise from the development of biotechnology.294
b. The Bill on Prohibition of Human Cloning and
Stem Cell Research and the Bill on Bioethics and
Safety
Beginning in early 2000, the developments in biotechnology to
produce internal organs, cells for transplantation, and treatment of
incurable diseases through human ES cell research began to be
competitively implemented.295 The domestic research team reportedly
created and cloned a human embryo using an egg and somatic cell
donated by a thirty-year-old woman, and cultivated it until the point
of implantation into the uterus.296 This success triggered public
debates on the permissible scope of stem cell research and cloning.297
They also increased concerns about the possibility of human
291. See Pak, supra note 290. There exist guidelines on research ethics and standards on
ethical reviews that are prepared by the relevant research institutes or the research evaluation
institutes themselves. For example, there are "The Guidelines for Research and Handling of
Human Stem Cells" prepared in September 2001 by the Research, Planning and Evaluation
Board on Health and Medical Technology established in the Ministry of Health and Welfare,
and "The Guidelines for Ethical Reviews on Stem Cell Research" prepared by the Ethics
Committee of the Stem Cell Research Center in October 2002. Id.




296. See Hong Sun-bee, Ethical Debate Expected After Ist Human Cloning Experiment
Here, THE KOREA TIMES,Dec. 15, 1998, available at
http://search.hankooki.com/times/times view.php?terms=cloning+code%3A+kt&path=hankook
il%2F 14_1%2F9812%2Ft4151520.htm.
297. See Pak, supra note 290.
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cloning.298  Public opinion surged toward demanding prompt
legislation to regulate human stem cell research.299
In response, bioethical and safety-related legislative proposals
were prepared by two ministries. The Ministry of Health and Welfare
("MHW") proposed the Life Science, Health and Safety, Ethics Act in
December 2000300 and the Ministry of Science and Technology
("MST") proposed the Bill on the Prohibition of Human Cloning and
Stem Cell Research in July 2002.301 Both proposed bills would ban
human cloning and impose criminal penalties including up to ten
years imprisonment. 30 2 However, both would have permitted stem cell
research using frozen embryos, categorized as disposable subjects,
and research using stem cells extracted from human body tissues.30 3
Moreover, both bills would mandate the creation of the National
Bioethics Commission ("NBC") under control of the President to
review bioethics-related matters.30 4 Additionally, the bills would ban
research employing SCNT or interspecies nuclear transfer, if
otherwise permitted.30 5
Three important differences between the two bills were noted:
who or what should be granted the authority 1) to determine the scope
of permissible research employing SCNT; 2) to administer the
research and development in biotechnology; and 3) and what
legislative actions should be taken regarding other bioethical issues.30 6
The bill proposed by MHW would bestow the authority to
administer the research and development-related issues on MHW
while the bill proposed by MST would bestow the authority on
298. See id.
299. See id.; Today's Editorial: Controversial Bill on Cloning, THE KOREA TIMEs, Dec.
11, 2000, available at
http://search.hankooki.com/times/times-view.php?terms=cloning+code%3A+kt&path=hankook
il%2Fktop%2F200012%2Ft20001211171435481126.htm.




301. See Lee Chi-dong, Maximum 10-Yr. Jail Term Suggested for Human Cloning
Experimentation, THE KOREA TIMES, July 18, 2002, available at
http://search.hankooki.com/times/times-view.php?terms=cloning+code%3A+kt&path=hankook
il%2Fktnation%2F200207%2Ft200207181720434111 0.htm.
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MST.30 7 According to the bill proposed by MHW, after the
appropriateness of the research had been considered by the Bioethics
Advisory Committee, the President would make the final
determination as to whether such research is permissible.0 8 In
contrast, the bill proposed by MST would enable NBC to review and
determine the issues on therapeutic embryonic cloning employing
SCNT or interspecies nuclear transfer with some flexibility.
309
Decisions would be made in response to international and national
trends and needs.
310
The bill proposed by MHW contained provisions regarding
embryo management, gene therapy, the protection of genetic
information, a gene bank, and genetic testing, while the bill proposed
by MST did not.311 The bill proposed by MST would place minimum
restrictions on relevant researchers and industries in order to foster the
further development of scientific technologies.' 12 The bill proposed
by MHW focused on the issues of the safety and dignity of human
beings in response to public concerns.313 The different positions taken
by the two ministries caused the passage of each bill to be delayed.314
In the wake of the July 2002 announcement by the Korean
branch of Clonaid and a domestic biotech company cooperating with
Clonaid that human cloning tests were being conducted within the
country,315 the Office for Government Policy Coordination mediated
the stalemate between the two governmental ministries in order to
reach a resolution to formulate a single bill.316 Accordingly, based on
the public opinions previously collected by the Korea Health Society
307. See id.




312. Id.; see also Lee Chi-dong, Minister Kim Aims High for Science Development, THE
KOREA TIMES, Nov. 21, 2002, available at
http://search.hankooki.com/times/times -view.php?terms=cloning+code%3A+kt&path=hankook
i3%2Ftimes%2Flpage%2Fnation%2F200211%2Fkt2002112117061910580.htm.
313. See Pak, supra note 290.
314. See id.
315. See Gov't Probes Human Cloning Experiments, THE KOREA TIMES, July 24, 2002,
available at
http://search.hankooki.com/tirnes/timesview.php?terms=cloning+code%3A+kt&path=hankook
il%2Ftimes%2F200207%2Ft2002072419034840110.htm; see also Na Jeong-ju, 'Korean
Woman May Deliver Cloned Baby', THE KOREA TIMES, Dec. 30, 2002, available at
http://search.hankooki.contimes/times view.php?terms=cloning+code%3A+kt&path=hankook
i3%2Ftimes%2Flpage%2F200212%2Fkt2002123017030610160.htm.
316. See Pak, supra note 290.
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Research Institute, MHW prepared the Act on Bioethics and Safety
("MHW bill") in July 2002."' 7 Notice of the proposed legislation was
published from September 24, 2002 to October 14, 2002 and a public
hearing regarding the MHW bill was held on October 9, 2002.318
In addition to its main provisions, the MHW bill included an
addendum. This addendum clarified a provisional measure for
embryo research which stated that existing research on SCNT as of
the effective date of the MHW bill, may be continued only upon
approval by the Minister of Health and Welfare. 319 This bill also
included a sunset provision, which mandated that the government take
appropriate actions, including amending the relevant regulations,
within three years from the date of the enactment of the MHW bill.32°
This provision required the government to review all of the provisions
of the MHW bill with respect to social and ethical changes in the
society and the development of biotechnology.32'
The draft of the Act on Bioethics and Safety was completed after
several rounds of expert forums and advice session, where opinions
from medical groups, legal groups, ethical community and citizen
groups were heard and considered.322 However, MST, joined by the
Ministry of Industry and Energy and the Ministry of Agriculture,
objected to this bill.323 This MHW bill received a wide range of
reactions and criticisms from different groups.
324
In particular, the Joint Campaign Group for a Rapid Enactment
of Bioethics Framework Act, an associated gathering of citizen
groups, urged the legislature to include provisions which would
prohibit embryonic cloning and interspecies hybridization without
exception. 325 The group called for provisions that would enhance the
status and function of the National Bioethics Committee.32 6 The Joint
Campaign Group filed a petition with the legislation containing its
own draft bill, "Bioethics and Biosafety Act," which amended the
317. See Soh Ji-young, Gov 't Finalizes Bill to Ban Human Cloning, THE KOREA TIMES,
Sept. 23, 2002, available at
http://search.hankooki.com/times/times-view.php?terms=cloning+code%3A+kt&path=hankook
i 1%2Fktnation%2F200209%2Ft20020923181922411 10.htm.






324. Pak, supra note 290.
325. See id.
326. See id.
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MHW bill.327 The amendments included upgrading the National
Bioethics Committee from an advisory body to a review and decision-
making body and banning human cloning and human embryonic
cloning through SCNT (including interspecies nuclear transfer).328
Biotechnologists opposed the MHW bill because it prohibited
embryonic cloning and interspecies hybridization. 329 They wanted
legislation that would ensure the freedom of research, while
prohibiting human reproductive cloning.330 Additionally, they feared
that passage of the bill would result in inefficient and rigid
bureaucratic practices that would impede the procedures for seeking
the Committee's review and permission.331
The MHW bill was originally scheduled to be submitted to a
regular fall session of the National Assembly in 2002.332 However, it
was withheld so that the governmental ministries could review the bill
in light of their policies and public opinion. 333 After reconvening for
review, the government produced a final combined bill, which allows
for the use of SCNT research (including interspecies transfer) for the
treatment of rare and incurable diseases that are prescribed by the
Presidential Decree. 4
2. The Bioethics and Biosafety Act of 2003
On October 14, 2003, after a year-long discussion within the
government and several rounds of public hearings, the government
bill, Bioethics and Biosafety Act ("2003 Act"), was referred to the
Health and Welfare Committee of the National Assembly.335 The bill
passed the National Assembly on December 29, 2003.336 The 2003
Act was based on the MHW bill and revised that bill to set up the










336. See Pak, supra note 290; Soh, supra note 283 ("Reproductive cloning will be banned
in the country .... ).
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rather than an advisory body.3 37 The 2003 Act also extended the
number of related ministers in the NBRC.338
The important provisions of the 2003 Act are: 1) the
establishment of the NBRC comprised of government Ministers and
scientific and non-scientific experts; 2) the creation of institutional
bioethics review boards; 3) a total ban on human cloning; 4) a ban on
embryonic cloning using SCNT with the exception of cases in which
the NBRC permits the use of the technology; 5) conditions and
criteria for utilizing excess embryos in research; 6) the prohibition of
inter-species hybridization; 7) the restrictions on genetic testing and
gene therapy; 8) the prohibition of creation of human embryos for any
purposes other than conception; and 9) the prohibition of the offering
of human eggs and sperms for trading or commercial purposes.339
a. Establishment of the National Bioethics Review
Committee
The 2003 Act provides that the NBRC shall be established under
the control of the President to respond to the President's inquiries
regarding the discipline and safety of bioscience and
biotechnology.340 The NBRC consists of sixteen to twenty-one
members. 34' The members shall include seven Ministers, less than
seven President-appointed members who are biotechnology or
medical science experts, and less than seven President-appointed
members from religious, philosophical, ethicists, legal, citizen, and
feminist groups.
342
The NBRC has the authority to review: 1) the national policy
regarding bioethics and safety; 2) the type, subject, and scope of
research utilizing excess embryos; 3) the type, subject, and scope of
research employing SCNT technology; 4) the categories of prohibited
genetic testing; 5) the diseases permitted for research and treatment
utilizing gene therapy; and 6) other matters related to
biotechnological research, development, and utilization that may have
serious ethical or social implications.343
337. See Pak, supra note 290.
338. See id.
339. Id.
340. See The Bioethics and Biosafety Act of 2003 (South Korea), Art. 6 (2003).
341. See id. Art. 7(1).
342. Id. Art. 7(3).
343. Id. Art. 6.
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b. Establishment of the Institutional Bioethics Review
Board
The 2003 Act mandates that an institutional bioethics review
board ("IRB") should be established for each embryo research
institute, gene bank, institute for gene therapy, and any other institute
for biotechnological research, development, and utilization that may
have serious ethical or social implications.3 ' An IRB will review the
ethical and scientific validity of biotechnology research proposals, the
proper acquisition of consent from a patient or a donor of sperm,
ovum, or other specimen, and the measures to protect personally
identifiable information in any form of a patient, or a donor of sperm,
345ovum, or other specimen.
c. Total Ban on Human Cloning and on Interspecies
Implantation
An act of implanting a cloned embryo through SCNT technology
into a woman's uterus, an act of maintaining the implantation of a
cloned embryo, or an act of leading to the birth of a cloned baby is
prohibited.346 A violator or a would-be violator shall be imprisoned up
to ten years.347 Participating in, inducing one into, or brokering any
act conducted for the purpose of human cloning is also prohibited and
penalized.348
Article 12 provides a ban on interspecies implantation.349
Additionally, the following acts are prohibited: 1) fertilizing human
eggs with animal sperms or vice versa; 2) transplanting a nucleus
taken from an animal somatic cell into a human anucleated egg; 3)
fusing a human embryo with an animal embryo; 4) fusing a human
embryo with different genetic information; or 5) implanting an
embryo created from the above acts into a human or animal uterus.350
344. Id. Art. 9.
345. Id.
346. ' See The Bioethics and Biosafety Act of 2003 (South Korea), Art. 11(1) (2003) ("an
act of creating an embryo by using an embryo, fetus, a living person, brain dead, or dead people
for the purpose of cloning a human" was prohibited).
347. See id. Art. 49.
348. Id. Art. 11(2), 50.
349. Id. Art. 12(1).
350. Id. Art. 12(2).
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d The Creation and Use of Human Embryos
Human embryos may not be created for any purpose other than
pregnancy.35' Moreover, human embryos shall not be produced by
any of the following acts of fertilization: 1) selecting a sperm to select
the sex of a baby; 2) using an egg or a sperm from a dead person; and
3) using a sperm or an egg from a minor. 352 Any person would be
prohibited from acquiring or transferring human sperm or eggs for
valuable consideration, such as monetary or property gains.353
Any medical institute that collects, conserves, or fertilizes human
sperm or eggs to produce embryos should be designated as an
Embryo-Producing Medical Institute by the Minister of Health and
Welfare.354
Excess embryos, which were created more than five years earlier
and that do not show the primary streak, may be used only for the
purpose of: 1) research on the treatment of infertility and development
of contraceptive techniques; 2) research on the treatment of rare or
incurable diseases, such as muscular dystrophy; and 3) research
prescribed by Presidential Decree after consideration by the NBRC.35 5
In order to study excess embryos pursuant to Article 17, a medical
institute should register as an Embryo Research Institute with the
Minister of Health and Welfare.356
e. Somatic Cell Nuclear Transfer
Somatic cell nuclear transfer is prohibited for any purpose other
than therapeutic research as stipulated in Article 17(2), i.e., research
on the treatment of rare or incurable diseases, such as muscular
dystrophy.357 The permissible scope of such therapeutic research may
be determined by Presidential Decree after consideration by the
NBRC. 358
f Genetic Testing
Any institute for genetic testing may not perform a genetic test
that is likely to mislead the tested person due to its uncertain value as
351. Id. Article 13(1).
352. See The Bioethics and Biosafety Act of 2003 (South Korea), Art. 13(2) (2003).
353. See id. Art. 13(3).
354. Id. Art. 14(1).
355. Id. Art. 17.
356. Id. Art. 18.
357. Id. Art. 22(1).
358. See The Bioethics and Biosafety Act of 2003 (South Korea), Art. 22(2) (2003).
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scientific proof, i.e., a genetic test for any physical appearance or
personality. 359. Any genetic test on embryos and fetuses may not be
conducted for any purpose other than diagnosing muscular dystrophy
and other genetic diseases prescribed by Presidential Decree. 360 Any
non-medical institute for genetic testing may not conduct genetic tests
related to the diagnosis of diseases other than those tests requested by
a medical institute.361
g. Protection and Use of Human Genetic Information
Genetic information may not be used to discriminate against any
person with respect to his or her social activities, such as obtaining
education, employment, promotion, and insurance.362 People may not
be forced to be subject to genetic tests or to be required to submit the
results of genetic test without an order pursuant to other laws and
regulations. 3
63
h. Aftermath of the Enactment of the Bioethics and
Biosafety Act
In March 2004, the Ministry of Health and Welfare launched the
Bioethics and Safety Task Force Team. 36 Its purpose is to create a
national framework regarding cloning research in order to ensure the
MHW's transparency and ethical integrity in relation to the Bioethics
and Biosafety Act that will take effect in 2005.365 While making it
clear that the recent cloning of human embryos by Professor Hwang's
team should not be used by religious cults to justify their case for
human cloning, the MHW supports research that is carried out within
the current legal boundaries and is designed to develop therapeutic
cloning to treat rare and intractable diseases.
366
The Task Force Team has been responsible for establishing and
running the NBRC.36 7 This responsibility has included putting
together a group of advisers, composed of professors and experts,
359. See id. Art. 25(1).
360. Id. Art. 25(2).
361. Id. Art. 25(3).
362. Id. Art. 31(1).
363. Id. Art. 31(2).
364. See Press Release, Ministry of Health and Welfare, Bioethics and Safety Task Force
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considering feedback from the group of advisors, creating a pool of
specialists who will work as members of the Committee, and
conducting a survey on sterility clinics, human embryo labs, and
DNA testing institutes around the country in order to frame a detailed
standard of personnel and facilities in these institutions, which will be
incorporated into the sub-regulations of the biological ethics law by
June 2005.368
On January 12, 2005, the MHW established the Bioethics Policy
Division to handle specific implementation of the 2003 Act.369 On the
same date, the government approved embryonic stem cell research led
by Seoul National University Professor Hwang Woo Suk.370 The
Ministry of Health and Welfare authorized an application, filed by the
research team led by Professor Hwang, for the registration of a
research institute on embryos and a research institute on the cloning
of stem cells from human embryos, as well as an application for
authorization for stem cell research.37' This authorization follows an
inspection of the status of laboratories as well as a review of relevant
documents. This was the first approval issued after the nation's new
bioethics law went into effect.372 This approval by the MHW is
expected to boost Professor Hwang's stem cell research under the
government management system.373
Arguably, the Korean government's hands-off attitude is the
Korean researchers' strongest advantage. 374 Moreover, most Koreans
reacted to the news of Hwang's cloning achievement with patriotic
fervor despite their awareness of the ethical issues.375 President Roh
368. Id.
369. See Press Release, Ministry of Health and Welfare, The Ministry of Health and




371. Id. However, this authorization shall remain valid only until a separate Presidential
decree on research on human stem cell cloning is announced following deliberation by the
National Bioethics Review Committee, which is planned to be organized around the end of
January. The Ministry of Health and Welfare has announced that the team needs to once again
undergo official procedures for the authorization of research in accordance with the provisions
in the 2003 Act following the promulgation of a new Presidential decree. Id.
372. See Gov't Approves Cloning Research by Geneticist Hwang, Korea Update, Jan. 21,
2005, at http://www.koreaemb.org/archive/2005/l1/econ/econ5.asp.
373. See id.
374. See B. J. Lee, Cloning College: South Korea's Biomedical Researchers, Unhampered
by Politics, Do World-class Research on the Cheap, NEWSWEEK INT'L, Mar. 1, 2005, available
at http://msnbc.msn.com/id/4339445/.
375. See id.
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has promised to "place top priority on the support of the
bioengineering industry. 376 According to the MHW, South Korea
will continue its stem cell research despite the anti-cloning resolution
of a United Nations committee.? The Korean government will
increase support for Seoul National University Professor Hwang Woo
Suk by nominating him as the nation's first "Supreme Scientist.
378
IV. PATENT PROTECTION OVER THE RESULTS OF HUMAN CLONING
AND EMBRYONIC STEM CELL RESEARCH
A. Requirements for Patentability under United States Patent
Law
Congressional authority to grant patents to individuals is derived
from the United States Constitution.379 The current version of the
Patent Act was enacted in 1952 and sets forth the requirements for an
invention to receive a patent.380 To be valid, the claimed invention
must comprise patentable subject matter,381 have utility,382 be novel,383
be non-obvious, 384 and enable others skilled in the art to practice the
376. Id.




378. See Kim Tae-gyu, Cloning Scientist Hwang to Get More Funding, THE KOREA
TIMES, Mar. 2, 2005, available at
http://search.hankooki.com/times/times-view.php?terms-cloning+code%3A+kt&path=hankook
i3%2Ftimes%2Flpage%2F200503%2Fkt2005030217325710160.htm.
379. See U.S. CONST. art. I, § 8, cl. 8.
380. See 35 U.S.C. §§ 100-103, 112 (2004).
381. See id. § 101 (2004). Patentable subject matter includes a "process, machine,
manufacture, or composition of matter, or any new and useful improvement thereof." Id.; see
also Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
The laws of nature, physical phenomena, and abstract ideas have been held not
patentable. Thus, a new mineral discovered in the earth or a new plant found in
the wild is not patentable subject matter .... Such discoveries are
"manifestations of... nature, free to all men are reserved exclusively to none."
Id. (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948)).
382. See 35 U.S.C. § 101 (2004). Claimed inventions must have a designated use to
establish utility. Id.; see also Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1366 (Fed.
Cir. 1999) ("The threshold of utility is not high: An invention is 'useful' under section 101 if it
is capable of providing some identifiable benefit.").
383. See 35 U.S.C. § 102(a) (2004) Claimed inventions must be novel, i.e., distinct from
prior art. Inventions may not be "known or used by others in this country... before the
invention thereof by the applicant for patent." Id.
384. See id. § 103 (2004) (stating that a claimed invention must embody a significant, non-
obvious advance over prior art to be valid).
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invention. 385 Additionally, any inventions that result from human
embryonic stem cell research and pertain to human biological
materials are subject to the human scope prohibition. 386
1. Patentable Subject Matter
To be valid, a patent must describe an invention that comprises
patentable subject matter.387 Patentable subject matter is construed
broadly as "anything under the sun that is made by man. 388
a. Results of Human Intervention
Products occurring in nature are not considered patentable
subject matter since they are subject to discovery rather than
invention. 389 Human input, however, may transform a product of
nature into a human-made product.390 A biological product cannot be
patented unless it has been sufficiently manipulated to cease being
"nature's handiwork., 391  By isolating pure cultures and
microorganisms, the inventors may create a valid claim in a
manufacture or process that does not occur separately and distinctly in
nature.392 Therefore, isolated DNA sequences that code for proteins
that function in detecting or treating diseases may be patentable
subject matter rather than a product of nature.39 3 The patentability of
inventions pertaining to biological organisms, including human
385. See id. § 112 (2004) (stating that the patent specification must include a written
description that enables others skilled in the relevant art to practice the invention).
386. See Damon J. Whitaker, The Patentability of Embryonic Stem Cell Research Results,
13 U. FLA. J.L. & PUB. POL'Y 361, 376-77 (2002).
387. See 35 U.S.C. §§ 101-103 (2004).
388. See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
389. See id.
390. Id.
391. Id. at 310 (holding that genetically engineered bacteria were patentable subject
matter). But cf Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (holding
that naturally occurring bacteria were not transformed into patentable subject matter when they
were merely isolated from nature).
392. See In re Bergy, 596 F.2d 952 (C.C.P.A. 1979), vacated, 444 U.S. 1028 (1980); In re
Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970) (upholding patents for isolated human and animal
prostaglandins); see also Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 104 (S.D.N.Y.
1911) (upholding patents for purified adrenaline isolated from surrounding tissues).
393. See generally U.S. Patent No. 5,977,333 (issued Nov. 2, 1999) (DNA Sequence
Encoding the Myotonic Dystrophy Gene and Uses Thereof); U.S. Patent No. 5,840,491 (issued
Nov. 24, 1998) (DNA Sequence Encoding the Machado-Joseph Disease Gene and Uses
Thereof); U.S. Patent No. 4,703,008 (issued Oct. 27, 1987) (DNA Sequences Encoding
Erythropoietin).
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matter, depends upon whether they result from sufficient human
intervention or manipulation.
b. The USPTO Policy of 'Human Scope' Prohibition
The current USPTO policy is set forth in two internal
documents. One is a 1987 statement by the USPTO that states,394
The Patent and Trademark Office now considers non-naturally
occurring non-human multicellular living organisms, including
animals, to be patentable subject matter within the scope of 35
U.S.C. 101 ....
A claim directed to or including within its scope a human being
will not be considered patentable subject matter under 35 U.S.C
101. The grant of a limited, but exclusive property right in a human
being is prohibited by the Constitution. Accordingly, it is
suggested that any claim directed to a non-plant multicellular
organism which would include a human being within its scope
include the limitation "non-human" to avoid this ground of
395
rejection.
And the second is the USPTO's, Manual of Patent Examining
Procedure ("MPEP") (Revised February 2003), section 2105:
"Patentable Subject Matter-Living Subject Matter" which states
that: "If the broadest reasonable interpretation of the claimed
invention as a whole encompasses a human being, then a rejection
under 35 U.S.C. 101 must be made indicating that the claimed
invention is directed to nonstatutory subject matter., 396
Recently, a USPTO official testified to the President's Council
on Bioethics:
When a patent claim includes or covers a human being, the
USPTO rejects the claim on the grounds that it is directed to non-
statutory subject matter. When examining a patent application, a
394. See Commissioner of Patents and Trademarks, Policy Statement on Patentability of
Animals, 1077 OFF. GAZ. PAT. OFFICE 24 (1987), reprinted in 9 DONALD S. CHISUM, CHISUM
ON PATENTS, app. 24 at 24-2 (1999).
395. Id. This notice responded to the Supreme Court's 1980 decision in Chakrabarty,
concluding that a modified microorganism, a non-natural bacterium, could be patented, and a
subsequent decision by the USPTO Board of Patent Appeals and Interferences in Ex parte
Allen, 2 U.S.P.Q.2d (BNA) 1425 (Bd. Pat. App. and Interferences 1987) that a multicellular
organism such as a modified oyster is therefore patentable as well. The USPTO sought to ensure
that these policy conclusions would not be misconstrued to allow a patent on a human organism.
396. See UNITED STATES PATENT AND TRADEMARK OFFICE, MANUAL OF PATENT
EXAMINING PROCEDURE § 2105 (8th ed., Aug. 2001), available at
http://www.uspto.gov/web/offices/pac/mpep/mpep e8r2_2100_508.pdf (latest revision May
2004).
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patent examiner must construe the claim presented as broadly as is
reasonable in light of the application's specification. If the
examiner determines that a claim is directed to a human being at
any stage of development as a product, the examiner rejects the
claims on the grounds that it includes non-statutory subject matter
and provides the applicant with an explanation. The examiner will
typically advise the applicant that a claim amendment adding the
qualifier, non-human, is needed, pursuant to the instructions of
MPEP 2105. The MPEP does not expressly address claims directed
to a human embryo. In practice, examiners treat such claims as
directed to a human being and reject the claims as directed to non-
statutory subject matter.
According to the USPTO's policy statement, "non-naturally
occurring nonhuman multicellular organisms," including animals, are
patentable subject matter while a "claim directed to or including
within its scope a human being will not be considered patentable
subject matter., 398 This ban on patenting human beings stems from
the constitutional prohibition of slavery, in other words, the
constitutional prohibition of property rights in humans.
399
c. Inventions Involving Human Matter
The USPTO has not adopted a policy to exclude all patents
which involve human material.40 0 The USPTO has issued patents
claiming human transfected cells and cell lines as compositions of
matter, finding human stem cell lines to be patentable subject
matter.40 However, it is doubtful that patent protection will be
available for further advanced composition of matter, such as human
organs, because the USPTO will likely find that any claims of such
inventions violate the USPTO's human scope policy statement.
40 2
Any inventions that pertain to human matter may still be patentable if
they are not identified as human beings.40 3 There is a controversy
397. See Testimony of Karen Hauda, United States Patent and Trademark Office, to the
President's Council on Bioethics (June 12, 2002), at
http://bioethicsprint.bioethics.gov/transcripts/jun02/une2 session5.html.
398. See Mark Jagels, Dr. Moreau Has Left the Island: Dealing with Human-Animal
Patents in the 21st Century, 23 T. JEFFERSON L. REv. 115, 131-32 (2000) (emphasis omitted).
399. See U.S. CONST. amend. XIII, § 1.
400. See Jagels, supra note 398, at 117.
401. See id. at 125.
402. See Whitaker, supra note 386, at 378.
403. See Jagels supra note 398, at 122-26.
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about whether chimeras and transgenic animal inventions would be
patentable.
i. Cell Lines and Transfected Cells
Patents for human cell lines and transfected cells are now widely
accepted.40 5 Chakrabarty v. Diamond was the landmark case which
decided with whether or not a bacterium, which neither was derived
from a human being nor contained a human gene, was patentable.4 °6
The court ruled that a live, human-made microorganism is patentable
subject matter under 35 U.S.C. § 101.407 The bacterium constituted a
"manufacture" or "composition of matter" within that statute, and was
40
not a hitherto unknown natural phenomenon. 08 Subsequently, a
patent claiming a bacterium expressing the human genes for
proinsulin409 and another patent claiming both bacteria and human
cell lines expressing the gene for human erythropoietin were issued.410
Patents for cell lines either derived from human or animal tumors or
that were artificially immortalized by manipulation were routinely
granted patents.411
In the case of Moore v. The Regents of the University of
California, the issue was whether or not the subject matter of the
Regents' patent-the patented cell line and the products derived from
it-was Moore's property.412 The Moore court concluded that a cell
line was patentable because it was the result of an inventive effort.
4 13
Developing primary cells (the cells taken directly from the body) into
a cell line is difficult, and is often an art with a low probability of
success.4 14 Arguably, the reasoning in Moore legitimizes the issuance
of process patents, but does not address the legitimacy of issuing
404. See id. at 125; see also Valerie J. Phillips, Half-Human Creatures, Plants &
Indigenous Peoples: Musings on Ramifications of Western Notions of Intellectual Property and
the Newman-Rifkin Attempt to Patent a Theoretical Half-Human Creature, 21 SANTA CLARA
COMPUTER & HIGH TEcH. L.J. 383, 385-87 (2005) (explaining chimeras and hybridization of
breeds).
405. Id. at 125-26.
406. See Diamond v. Chakrabarty, 447 U.S. 303 (1980).
407. See id. at 308-18.
408. Id. at 308-10.
409. See U.S. Patent No. 4,431,740 (issued Feb. 14, 1984).
410. See U.S. Patent No. 4,703,008 (issued Oct. 27, 1987).
411. See Moore v. Univ. of Cal., 793 P.2d 479 (Cal. 1990); U.S. Patent No. 4,438,032
(issued Mar. 20, 1984).
412. See Moore, 793 P.2d at 488-89.
413. Id. at 492-93.
414. Id. at 481-82 n.2.
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product patents for a cell line.415 However, cell lines have generally
been exempt from the policy prohibiting patents over living matter.
416
It has been estimated that more than one thousand patents involving
human genes expressed by bacteria, yeast, or human cell lines have
been issued . 7
The amount of human genetic material is not determinative of
human essence for purposes of deciding the patentability of subject
matter.418 The USPTO has allowed patents on human cell lines that
contain purely human DNA.4 19 The USPTO may exclude any intact
organism, presumably a mammal that expresses human genetic
material, as inappropriate subject matter.420 As long as a cell line is
incapable of differentiating into a human, it would not be considered a
human being under the USPTO guideline. 421
ii. Multicellular Organisms Containing Human
Material
Multicellular organisms have been manipulated to contain
human genes. A number of patents have been issued for transgenic
animals, which are produced by the introduction of a human gene into
a fertilized animal ovum or early embryo.422 For example, a mouse
which had been genetically infused with a human cancer gene, for the
purpose of experimentation, was deemed patentable.423 The mouse
was novel under Chakrabarty because of its acquired cancer
susceptibility and inserted human gene.424 The mouse had a utility as
an animal model for research on carcinogenesis. 425 It was non-obvious
because of the novel technology employed and because of the newly
identified human oncogenes that were introduced into the mouse.42 6
Hundreds of patents involving animals into which human genes have
415. See Jagels, supra note 398, at 129.
416. See id. at 130.
417. See Thomas A. Magnani, The Patentability of Human-Animal Chimeras, 14
BERKELEY TECH. L.J. 443,444 (1999).
418. See Jagels, supra note 398, at 129.
419. See id. at 125.
420. Id. at 129.
421. Id.
422. See id. at 124.
423. See U.S. Patent No. 4,736,866 (issued Apr. 12, 1988). The patent is known as the
"Harvard transgenic mouse." The claims included animals into which human oncogenes were
introduced.
424. See Jagels, supra note 398, at 132.
425. See id.
426. See id.
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been introduced have been granted. 427 The utility of the animals tends
to be determined based on their commercial value.428
Multicellular organisms have also been manipulated to contain
human cells by engrafting human ES cells or adult stem cells into a
host organism 429 or by combining human and non-human ES cells.
430
For example, an animal model where mice with severe combined
immune deficiency were given human bone marrow transplants was
deemed patentable.43' In contrast, in 1998, techniques for combining
ES cells of humans and animals to produce a chimera were not
patentable.432 The USPTO did not reject the patent based upon public
policy and moral reasons.4 33 However, the USPTO issued a media
advisory stating that a "human/non-human chimera could.., fail to
meet the public policy and morality aspects of the utility
requirement. ' '434 The examiner stated, "[t]he [US]PTO believes that
Congress did not intend 35 U.S.C. to include the patenting of human
beings. Since applicant's claimed invention embraces a human being,
it is not considered to be patentable subject matter.''435 In fact, the
claims were broadly written, including a variety of different
combinations of human and animal cells as well as both embryos and
fully developed organisms that would result from the combinations.436
Apparently, the claimed invention could be considered human even
when an immeasurably minute amount of non-human material is
present.437 Therefore, the extent of patentability of the results of
manipulation of multicellular organisms containing human cells
appears unsettled.438 A claim will very likely be rejected if it
427. Id.
428. See id. at 133.
429. See id. at 123.
430. Jagels, supra note 398, at 133.
431. See U.S. Patent No. 5,652,373 (issued July 29, 1997) (Engraftment and Development
of Xenogenic Cells in Normal Mammals Having Reconstituted Hematopoietic Immune
Systems).
432. See Patent Application is Disallowed as 'Embracing' Human Being, 58 PAT.
TRADEMARK & COPYRIGHT J. (BNA) 203, 203 (June 17, 1999).
433. See Jagels, supra note 398, at 133; see also Media Advisory No. 98-6, United States
Patent and Trademark Office, Facts on Patenting Life Forms Having a Relationship to Humans
(Apr. 1, 1998), at http://www.uspto.gov/web/offices/con/speeches/98-06.htm.
434. See Jagels, supra note 398, at 133 (quoting Media Advisory No. 98-6, supra note
433).
435. See id. at 134.
436. See id. at 133.
437. See id. at 133-34.
438. Id. at 125.
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potentially covers a composition made predominantly of human
matter.439
iii. Patentability of Human Cloning and
Embryonic Stem Cell Research
The extent of patentability of potential claims from human
cloning and ES cell research has not yet been fully explored in the
United States because of the continued governmental ban on human
cloning and ES cell research. Possible claims include product claims
on various human material created from the research, and process
claims that include methods on how to obtain and how to use the
product. Product claims and process claims will not necessarily have
the same outcome with respect to whether they are patentable subject
matter.44 °
As discussed above, currently no statutory foundation exists for
excluding any invention that results from human cloning and
embryonic stem cell research because of a subject matter rejection.44 1
Title 35 of the United States Code does not provide the USPTO with
a basis for making this determination, and does not expressly address
human subject matter.442 The USPTO has issued patents claiming
human stem cell lines as a composition of matter." 3 However, it is
uncertain that the USPTO will grant patents claiming various human
organs as composition of matter due to its human scope policy
statement.4 " Ultimately, whether any product or composition of
matter is considered patentable subject matter depends upon how the
scope of a human being is defined.
445
Debates on whether human material created by the cloning
process will be considered a human being have frequently focused on
whether a two-week-old embryo, asexually produced by SCNT, is a
human being." 6 The biotechnology industry does not consider human
439. Id. at 133-34.
440. Jagels, supra note 398, at 136; see also Whitaker, supra note 386, at 378.
441. See Jagels, supra note 398, at 136.
442. See id.
443. See, e.g., U.S. Patent No. 6,090,622 (issued July 18, 2000) (Human Embryonic Stem
Cell Lines).
444. See Whitaker, supra note 386, at 378.
445. See Jagels, supra note 398, at 136.
446. See Dianne N. Irving, Analysis: Stearns' Congressional Human Cloning Fairy Tale
"Ban "; New Age and Transhumanist Legislation for "Converging Technologies"?,
Lifeissues.net, at http://www.lifeissues.net/writers/irv/irv_77 stearncloningtalel.html (last
visited Mar. 20, 2005); see also Testimony of Michael D. West, President and CEO of
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material created by SCNT a human being.447 Senator Feinstein (D-
CA) referred to two-week-old cloned embryos as unfertilized eggs,
and asserted that such an unfertilized egg is not capable of becoming
a human being." 8 It has not been debated that cloned mammals are
created via asexual reproduction through the laboratory manipulation
of a nucleus taken from a single parent and are unfertilized, in the
sense that they are not created by the union of sperm and egg.449
In contrast, the National Right to Life Committee includes any
human embryo, fetus, child, or adult as members of the species Homo
sapiens in any discussion regarding human cloning issues. 450 The
Committee asserts that one of these cloned embryos can be born as a
human baby if implanted into a uterus, just like Dolly the Sheep and
other cloned mammals. 451 Furthermore, it argues that it cannot be said
that an unfertilized human embryo is not a human being if such
embryo is implanted, develops through the pre-natal period, is born,
and lives.452 The Committee finds some support for their argument
from the 1997 report of President Clinton's National Bioethics
Advisory Commission on Cloning Human Beings that states "It]he
Commission began its discussions fully recognizing that any effort in
Advanced Cell Technology, Inc., to the Subcommittee on Labor, Health and Human Services,
and Education, and Related Agencies (July 18, 2001), at
http://www.advancedcell.com/testimony-2001-07-18.htm ("[A]n individual human life, as
opposed to merely cellular life, begins with the primitive streak (i.e., after 14 days of
development).") (last visited Mar. 20, 2005). The appearance of the primitive streak at around
fourteen days of the embryonal age is considered important biologically and developmentally
because it signals the formation of three germ layers in an embryo that differentiate into all
types of human cells. Id.
447. See Biotechnology Industry Organization, The Value of Therapeutic Cloning for
Patients, at http://www.bio.orgfbioethics/background/tcloning.asp (last visited Mar. 20, 2005)
("[SCNT] involves removing the nucleus of an egg cell, replacing it with the material from the
nucleus of a 'somatic cell'.... This egg cell is never fertilized by sperm ... stem cells can be
extracted from it 5-6 days later .... ); see also Irving Weissman, A Message from the Director
of the Institute of Cancer/Stem Cell Biology and Medicine at Stanford, THE STANFORD REPORT,
Jan. 22, 2003, at
http://news-service.stanford.edu/news/2003/january22/message.html ("Technically, one should
not use the term embryo to describe a blastocyst produced by nuclear transfer as an embryo,
because it was not the product of sperm and egg ... ").
448. 148 CONG. REc. S5563, S5580 (daily ed. June 14, 2002) (statement of Sen.
Feinstein).
449. See Beardsley, supra note 119; see also THE PRESIDENT'S COUNCIL ON BIOETHICS,
HUMAN CLONING AND HUMAN DIGNITY: AN ETHICAL INQUIRY 57-73 (July 2002), available at
http://www.bioethics.gov/reports/cloningreport/background.html.
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humans to transfer a somatic cell nucleus into an enucleated egg
involves the creation of an embryo, with the apparent potential to be
implanted in utero and developed to term."
453
(1)Product Claims
Unmodified human cells and tissues, as they exist in vivo, cannot
be patented under current United States law.454 For example, mature
egg cells, mature sperm cells, zygotes, blastocysts, totipotent or
pluripotent stem cells, embryos, fetuses, and humans are not
patentable.455 In contrast, modified cells such as enucleated or
genetically modified egg cells, sperm cells, somatic cells and tissues,
cultured tissue or synthetic organs are patentable.456
Human embryonic stem cell lines derived from SCNT would fall
under the same conditions of patentability as cell lines, genes, and
other products of natural derivation.457 Patenting special types of stem
cells that have been identified for the first time as useful for treatment
and that can be isolated by a specific process, e.g., based on antigenic
markers, is no different than the commercialization of the human
body by patenting of novel genes.458 Moreover, the process of
isolating, expanding, and characterizing human ES cell lines makes
the cell lines eligible to receive patent protection under governing
case law.459 Furthermore, it does not appear that the USPTO considers
a claim encompassing a human stem cell line to be directed to, or
included within its scope, a human being.4 60 Human adult stem cells,
identified in adult bone marrow, were patentable as compositions of
matter.461 The issuance of such patents, and the lack of challenges to
their validity, proves that the patentability of such human cells and
biological materials is not within the human scope of the USPTO's
453. See National Right to Life, Are Human Clones Really "Human"? at
http://www.nrlc.org/KillingEmbryos/arecloneshuman.html (last visited Feb. 7, 2005).
454. See Biotechnology Industry Organization, supra note 169.
455. See id.
456. Id.
457. See R. Stephen Crespi, Patenting and Ethics-A Dubious Connection, 85 J. PAT. &
TRADEMARK OFF. Soc'Y 31, 46 (Jan. 2003).
458. See id.
459. See Whitaker, supra note 386, at 376-77.
460. See id. at 377.
461. See Warren D. Woessner, The Evolution of Patents on Life-Transgenic Animals,
Clones and Stem Cells, 83 J. PAT. & TRADEMARK OFF. SOC'Y 830, 841 (Nov. 2001) (referring
to U.S. Patent No. 4,714,680 (issued Dec. 22, 1987) that claims a preparation containing
hematopoietic stem cells: "4. A suspension of human cells from blood comprising pluripotent
lympho-hematopoietic stem cells substantially free of mature lymphoid and myeloid cells.").
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regulations.462 Indeed, a purified preparation of human embryonic
stem cells, per se, was deemed patentable on March 14, 2001 .463
The first issue regarding the patentability of cloned embryos,
human tissues, and organs developed from cloned embryos, is
whether or not those in vitro products are manmade, rather than a
product of nature.464 To be patentable in accordance with existing law,
the embryos "must be 'given a new form, quality, properties or
combination not present in the original article existing in nature.
'465
Presumably, only embryos and stem cells that have been modified by
in vitro treatment or genetic modification are considered fit patentable
466
subject matter. Growing oocytes in culture and performing SCNT
on the oocytes would meet those requirements.467
It may be argued that the difference between SCNT and in vitro
fertilization is not material; therefore, if in vitro fertilization does not
transform a human embryo into a human invention, then SCNT does
not transform a cloned embryo into an invention, either. Moreover,
cloned embryos seem to retain the potential to develop to term if
implanted in utero just like any fertilized ovum. However, it may still
be argued that the difference between SCNT and in vitro fertilization
is significant. It may also be argued that SCNT involves more
extensive and drastic genetic manipulation than in vitro fertilization.
Whether cloned embryos, and human tissues and organs derived
from them are patentable human subject matter is controversial and
uncertain.468 The debates focus on the USPTO's human scope
462. See Whitaker, supra note 386, at 378.
463. See Woessner, supra note 461, at 840 (referring U.S. Patent No. 6,200,806 (issued
Mar. 13, 2001) that claims
1. A purified preparation of pluripotent human embryonic stem cells which (i)
will proliferate in an in vitro culture for over one year, (ii) maintains a karyotype
in which the chromosomes are euploid and not altered through prolonged culture,
(iii) maintains the potential to differentiate to derivatives of endoderm,
mesoderm, and ectoderm tissues throughout the culture, and (iv) is inhibited from
differentiation when cultured on a fibroblast feeder layer).
464. See Ex parte Allen, 2 U.S.P.Q.2d (BNA) 1425 (Bd. Pat. App. and Interferences
1987), aff'd, 846 F.2d 77 (Fed. Cir. 1988); Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980)
(holding that genetically engineered bacteria were patentable subject matter); cf Funk Bros.
Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (holding that naturally occurring
bacteria were not transformed into patentable subject matter when they were merely isolated
from nature).
465. See Woessner, supra note 461, at 830 (quoting a statement by the USPTO days after
Ex parte Allen was decided).
466. See Biotechnology Industry Organization, supra note 454.
467. See id.
468. See Whitaker, supra note 386, at 376.
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prohibition 469 which was confirmed by recent amendment. 470 The
developmental stages of an embryo involved, as discussed earlier, the
mode of sexual reproduction, and the potential to develop to term
would be relevant to debates on whether the claimed product violates
the human scope policy statement.
(2)Process Claims
The products and methods for cloning, in general, are usually
patentable.47' Methods of nuclear transfer, methods of making a
transgenic mammal, methods of culturing gametes, zygotes, or
embryonic tissues, methods of genetically modifying cells or tissues,
etc. have been patented.472 The USPTO has awarded patents for the
creation of genetically modified non-human mammals via cloning.473
Moreover, the USPTO has issued a patent on a method for turning
unfertilized eggs of mammals into embryos, which would extend to
human embryos cloned by this method.474 The extension occurs
because a nonhuman disclaimer is not included in the claims of the
patent and it specifically mentions the use of human eggs.475 Patents
have also been issued for the methods utilized in the isolation and
purification of stem cells and in corresponding research.476
The patentability of other types of possible end-products of
human ES cell research that do not directly relate to human material
appears to be more firmly established.4 77 Applications in the areas of
cell culture, tissue transplantation, drug discovery, and gene therapy
have been patented. 478 As long as inventions do not claim human
469. See id. at 378.
470. See Consolidated Appropriations Act of 2004, Pub. L. No. 108-199, § 634, 118 Stat
3, 101 (204).
471. See Biotechnology Industry Organization, supra note 454.
472. See id.
473. See U.S. Patent No. 5,945,577 (issued Aug. 31, 1999).
474. See U.S. Patent No. 6,211,429 (issued Apr. 3, 2001).
475. See id. at claim 12.
476. See U.S. Patent No. 6,602,711 (issued Aug. 5, 2003) ("10. The method of claim 1,
wherein the primate embryonic stem cells are human embryonic stem cells and the primate
embryoid bodies are human embryoid bodies").
477. See Whitaker, supra note 386, at 378.
478. See U.S. Patent No. 6,534,052 (issued Mar. 18, 2003) (claiming a method for
improving cardiac function in a living mammalian subject after the occurrence of a myocardial
infarction within the heart tissue by implanting embryonic stem cells); see also U.S. Patent No.
6,562,619 (issued May 13, 2003) (claiming a method of isolating primordial germ cells from
human embryonic tissue, such as from the gonadal ridges of human embryo; a method of
producing human pluripotent embryonic germ cells); U.S. Patent No. 6,569,421 (issued May 27,
2003) (claiming a treatment of brain damage by cellular transplantation; a method for treating a
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compositions as an end product and the claims meet all of the
patentability requirements set forth in the Patent Act, the inventions
are patentable, even if the research methods involve the employment
of human ES cells and result in products that fall under the human
scope prohibition.479 Thus, there seems to be an apparent acceptability
of process patents.
2. Utility
"Whoever invents or discovers any new and useful process,
machine, manufacture, or composition of matter, or any new and
useful improvement thereof' may apply to obtain a patent on that
invention.48 ° In Brenner v. Manson, the Supreme Court held, that in
light of the policy considerations underlying the statutory requirement
for utility, a patentable process must be useful and that a new
chemical process was not inherently useful by virtue of its being a
contribution to scientific researchers.48' Proof of the practical utility
of the compound produced by the process is an essential element in
establishing a prima facie case for its patentability. 482 The court
required that "until a process is refined and developed [such that]
specific benefit exists in currently available form there is insufficient
justification for permitting an applicant to engross what may prove to
be a broad field.' '483 However, the fact that an invention has only
limited utility and is only operable in certain applications is not
grounds for finding lack of utility, and some degree of utility is
sufficient for patentability under patent law.484 Potential utility485 or
motor, sensory and/or cognitive deficit by administering a composition comprising pluripotent
cells into the damaged brain in a region contralateral to that containing the site of damage); U.S.
Patent No. 6,607,720 (issued Aug. 19, 2003) (claiming a therapeutic application of genetically
altered mammalian embryonic stem cells and their living progeny for improving cardiac
function after myocardial infarction); U.S. Patent No. 6,630,349 (issued Oct. 7, 2003) (claiming
an isolated preparation of stable pluripotent trophoblast stem cell lines and uses of the cell
lines).
479. See Whitaker, supra note 386, at 378.
480. See 35 U.S.C. § 101 (2004).
481. Brenner v. Manson, 383 U.S. 519, 534-36 (1996).
482. See Brenner, 383 U.S. at 534-35.
483. See id.
484. See Envirotech Corp. v. Al George, Inc., 730 F.2d 753, 762 (Fed. Cir. 1984).
485. See Brenner, 383 U.S. at 534-35 (invalidating patent for a steroid because its asserted
utility was speculative, based only on similarity to a compound that showed activity in inhibiting
tumors).
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usefulness for research purposes alone, do not satisfy the utility
486requirement.
Courts have debated the appropriate application of Brenner to
define standards for assessing utility in the areasof biotechnology. For
example, in Nelson v. Bowler, the court held it was unnecessary for
appellant to establish a specific therapeutic use, but that evidence of
any utility, such as adequate proof of any pharmacological activity,
was sufficient to show practical utility.487 In contrast, in Cross v.
lizuka, the court held that a consideration in the determination of
whether a patent should be granted is the benefit derived by the public
from an invention with substantial utility.488 In Ex parte Balzarini, the
applicants claimed compounds with activity against the AIDS virus,
by showing in vitro activity.489 However, the USPTO denied issuing a
patent due to the absence of demonstrating in vivo efficacy.49 ° In
response to the results of Balzarini and similar decisions that
excessively restricted the patentability of potentially valuable
compounds at early stages of development, the USPTO issued new
utility guidelines in 1995. The new utility guidelines provided that an
application is rejected on the basis of utility defects if no credible
assertion of specific utility for the claimed invention is made by the
applicant, and the claimed invention does not have a well-established
utility. 49' Under the 1995 utility guidelines, the USPTO has the
burden of a prima facie showing that the claimed invention has no
utility. 492 This showing must be based on specific evidence that
supports any fact-based assertions.493 Once the USPTO has met its
burden, the applicant bears the burden of rebutting it.
494
In deference to the USPTO's expertise and in the absence of
binding authority to the contrary, courts applied the 1995 utility
guidelines to assess utility of the claimed invention.495 The USPTO's
486. See id. at 536 (stating that "a patent is not a hunting license. It is not a reward for the
search, but compensation for its successful conclusion.").
487. See Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980).
488. See Cross v. lizuka, 753 F.2d 1040 (Fed. Cir. 1985).
489. See Ex parte Balzarini, 21 U.S.P.Q.2d (BNA) 1892, 1894 (Bd. Pat. App. and
Interferences 1991).
490. See id. at 1895-96.
491. See Utility Examination Guidelines, 60 Fed. Reg. 36,263, 36,264 (July 14, 1995).
492. See id. at 36,265.
493. See id.
494. See id.
495. See Cross v. Iizuka, 753 F.2d 1040, 1044 n.8 (Fed. Cir. 1985) ("[Qluestions regarding
utility are factual in nature... and are to be determined in the first instance by the [US]PTO, the
agency with the expertise in this regard."); In re Brana, 51 F.3d 1560, 1568 (Fed. Cir. 1995)
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2001 Utility Examination Guidelines require a patent applicant to
demonstrate either a "well-established" utility or a "specific,
substantial, and credible" utility.4 96 To satisfy this standard, the
applicant is required to affirmatively assert the utility of the claimed
invention in the claims and the supporting written description.49
Thus, courts will assess the contested claims to determine whether
they demonstrate "well-established" or "specific, substantial, and
credible" utility.
498
Well-established utility requires that a person of ordinary skill in
the art will immediately appreciate the invention's asserted utility,
and that the utility is specific, substantial, and credible.4 99 Courts have
found well-established utility in devices that were clearly effective in
carrying out identifiable functions, including window fasteners and
500oil-drilling equipment.
Substantial and specific utility standards require that the
invention be useful for a particular purpose, and that the asserted
utility for a particular practical purpose be considered credible by a
person of ordinary skill in the art °0 "Throw-away," "insubstantial,"
and "nonspecific" utilities fail these standards.50 2 A claim has credible
utility if one of ordinary skill in the art would consider the asserted
utility to be reasonable in view of the disclosure and any other
evidence of record (e.g., test data, affidavits or declarations from
experts in the art, patents, or printed publications) that is probative of
the applicant's assertions. °3  Additionally, if a compound
demonstrates credible activity in the treatment of a specific disorder,
this effect suffices to establish substantial and specific utility.
5 4
("[W]ith regard to questions of fact, we defer to the Agency unless its findings are 'clearly
erroneous."').
496. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1098 (Jan. 5, 2001).
497. See id.
498. Id.
499. See id.; see also Nathan Machin, Prospective Utility: A New Interpretation of the
Utility Requirement of Section 101 ofthe PatentAct, 87 CAL. L. REV. 421, 428 n.37 (1999).
500. See Elliott Core Drilling Co. v. Smith, 50 F.2d 813, 816 (9th Cir. 1931) (finding well-
established utility in a commercially successful rotary core drill that did not show sufficient
novelty for patent protection); see also Edwards v. Dayton Mfg. Co., 257 F. 980, 984 (6th Cir.
1918) (finding well-established utility for highly successful window holding and fastening
devices that lacked new elements).
501. See Utility Examination Guidelines, 66 Fed. Reg. at 1098.
502. See id.
503. Id.
504. See In re Brana, 51 F.3d 1560, 1565 (Fed. Cir. 1995).
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It would not be difficult for biotechnological inventions to meet
the utility requirement under the USPTO guidelines. 50 5 Most
biotechnological inventions that are designed to produce
commercially marketable products would disclose any readily
apparent utility or at least one particular practical utility.50 6 With
respect to results of human ES cell research scientists already see
their potential uses in reparative/regenerative medicine, not only as a
research tool, but also as a therapeutic tool.50 7 It is not necessary to
establish immediate clear-cut applications of an invention derived
from human ES cell research because the well-established utility of
the invention need not to be shown.508 The claims only need to show
any specific practical utility of an invention such as, the utility of the
invention as an accepted, well-established research tool or therapeutic
procedure. 50 9
Nevertheless, the USPTO appears to be willing to invoke an
alternative aspect of the utility requirement - the morality doctrine. 510
It has been suggested that there is some uncertainty as to the scope of
this doctrine regarding stem cells.51 Admittedly, this doctrine refers
only to the cloned embryo itself and not to entities derived from the
embryo.51 2 However, harvesting stem cells from a human embryo
with the intention to use them as the source of an intermediate or final
product in a commercial-type context may not escape the scope of
this doctrine simply because it is technology downstream from the
embryonic source. 513 Furthermore, if the origin of the cells is to be
disclosed in the patent application the relevance of this requirement
will be clear.
514
505. See Jagels, supra note 398, at 137.
506. See id.
507. See Hwang et al., supra note 2; see also THE NATIONAL INSTITUTES OF HEALTH,
STEM CELL INFORMATION: STEM CELLS AND DISEASES, at
http://stemcells.nih.gov/info/health.asp (last modified on June 10, 2004) [hereinafter STEM
CELLS AND DISEASES].
508. See Utility Examination Guidelines, 66 Fed. Reg. at 1098.
509. See id.; see also STEM CELLS AND DISEASES, supra note 507 (stating potential utility
in human development research with respect to both physiological differentiation and abnormal
cell division and differentiation such as cancer and birth defects; and in developing a new drug
test model, and cell-based therapies for various diseases such as Parkinson's and Alzheimer's
diseases, spinal cord injury, stroke, bums, heart disease, diabetes, osteoarthritis, rheumatoid
arthritis, etc.).
510. See Media Advisory No. 98-6, supra note 433.
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a. Morality Doctrine
According to a USPTO media advisory, an invention of human-
related organisms could specifically fail to meet the utility
requirement under the morality doctrine. 5 15 This assertion was based
on the seldom used "morality doctrine," which states that an invention
cannot be useful if it is designed for an immoral use. The morality
doctrine, which originated as a part of the utility requirement, 516 has
been applied and interpreted erratically partially due to the changes in
social concepts of morality.51 7 Some courts have applied a balancing
test between the potential beneficial uses and immoral uses to
determine any apparent utility518 while some courts appear to have
abandoned the morality doctrine entirely.5 19 Therefore, the status of
the morality doctrine is currently in dispute.5 20 Moreover, because
Title 35 of the United States Code "does not specifically require
moral balancing" and "social concepts of morality are in a continuous
flux," courts have been "reluctant to use the morality doctrine as the
sole basis for rejecting patent applications., 521 However, in light of
their media statement, the USPTO appears to be willing to invoke the
morality doctrine in determining utility of any invention pertaining to
human material.522
3. Novelty
A patented invention will not issue unless the invention is
novel.52 3 The novelty requirement both protects and rewards original
inventors of an innovative device and prevents the grant of a patent to
a device that is not innovative.524
In most cases involving human materials, this requirement would
not seriously restrict patentability.52 5 Section 102 requires that no
515. See Media Advisory No. 98-6, supra note 433.
516. See Jagels, supra note 398, at 138 (citing Lowell v. Lewis, 15 F. Cas. 1018 (C.C.D.
Mass. 1817) (No. 8,568).
517. See id.
518. Id. (citing Fuller v. Berger, 120 F. 274, 275 (7th Cir. 1903).
519. See Jagels, supra note 398, at 138 (citing Whistler Corp. v. Autotronics, Inc., 14
U.S.P.Q.2d (BNA) 1885, 1886 (N.D. Tex. 1988)).
520. See Jagels, supra note 398, at 138.
521. See id.
522. See Media Advisory No. 98-6, supra note 433.
523. See 35 U.S.C. § 102(a), (e), and (g) (2004).
524. See I DONALD S. CHISUM, CHISUM ON PATENTS § 3.01 (2004) ("An invention must
be new at the time of discovery by an original inventor to be patentable.").
525. See Jagels, supra note 398, at 139.
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single prior invention contains all of the elements of the claimed
invention. 26 In Chakrabarty, a cell line derived from a tumor could
not be said to be novel because it would have been derived from a
naturally occurring source.52 7 Rather, it could be said to be rendered
an invention over the original cell because it has itself been changed
through the art of growing the cell in culture. 28 In cases involving
newly identified, but naturally occurring genes, the genes have been
considered novel if they were purified and isolated in an expressible
form because they were no longer in their original context.
529
Moreover, even a non-novel gene may create a novel invention when
introduced into another species because it creates a non-natural life
form.5 30 "Accordingly, the novelty requirement may only prevent
approval of a patent if the disputed human composition has already
been produced., 53 1 If a similar, but non-human invention has been
produced, it may trigger the non-obviousness requirement, but not the
novelty requirement.
532
It should be considered whether a cloned embryo or ES cell line
is novel over the human oocyte donor and cumulus cells 533 that
certainly existed prior to the invention of the cloned embryo. The
cloned embryo or ES cell line is not identical to either an oocyte or a
cumulus cell because the embryo and the ES cells were produced
when the oocyte was enucleated with the nucleus from the cumulus
cell. Moreover, the existence of the embryo itself or human ES cells
in vitro would establish novelty over any naturally occurring
derivatives of a human oocyte and/or cumulus cell in vivo. Therefore,
any human material resulting from SCNT, which is altered from its
original form and isolated from it original context, should be deemed
novel and thus, patentable.
4. Non-Obviousness
The claimed invention should represent an advance over the
prior art to deserve patent protection.5 34 Where "the differences
between the subject matter sought to be patented and the prior art are
526. See id. at 139-40.
527. See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
528. See id.




533. See Hwang et al., supra note 2, at 1670.
534. See Eisenberg, supra note 172, at 730.
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such that the subject matter as a whole would have been obvious at
the time the invention was made to a person having ordinary skill in
the art," the invention is obvious and not patentable.535 This
requirement is increasingly difficult to satisfy as scientific knowledge
advances in a field.536 It is likely that scientific advances in
biotechnology and related fields will make future developments
obvious as of the time they are identified.
537
"[A]n invention might be non-obvious... : (1) if there is no
reasonable expectation of success; (2) if arriving at the invention
requires undue experimentation... ; or (3) if the prior art merely
suggests exploration of a promising field of experimentation and
gives only general guidance as to the particular form of the
claimed invention or how to achieve it."
538
The critical inquiries are whether success was reasonably
predictable based on the prior art, and whether the inventor has to
develop a new technique to create the invention.539 If the prior art led
to the production of the claimed biological invention, and there is a
reasonable expectation that the invention can be carried out
successfully, the invention would fail to satisfy the non-obvious
requirement.5 40  Separate analysis may be done on the non-
obviousness of the compound itself and on the non-obviousness of the
process of obtaining the compound.
541
It would be difficult to predict all of the variations in ES cell
lines or cloned embryos correctly. It is questionable whether a person
having ordinary skill in the art could anticipate all the unique aspects
of ES cell lines or cloned embryos and all aspects of their usefulness,
as therapeutic or research tools, based on prior art (e.g., other stem
cell lines or cloned non-human animals.) Although it may have been
obvious for an inventor to experiment with disclosed stem cell lines
or cloned embryos to locate unique differentiation and activities, the
invention is not rendered invalid because research findings are
unpredictable.542
535. See 35 U.S.C. § 103(a) (2004).
536. See Eisenberg, supra note 172, at 730.
537. See id.
538. See id. at 732-33.
539. Id. at 734.
540. Id.
541. Id. at 734-35.
542. See In re O'Farrell, 853 F.2d 894, 903 (Fed. Cir. 1988) (although a DNA sequence of
gene coding for a monkey protein was disclosed, the sequence of the human gene and protein
chain was neither obvious nor predictable, even if the area was an obvious target for research).
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Additionally, the claimed invention is not obvious under the
"similar compound" test. 543 Cloned embryos or ES cell lines differ in
their functions based on minor differences in genetic and epigenetic
material and based on environmental factors. 544 Despite substantial
similarity, the claimed invention may demonstrate unexpected new
properties.545 Accordingly, obviousness would not invalidate any
claimed invention derived from a human ES cell, at least until human
cloning and ES cell research employing SCNT become commonplace
and obvious to those skilled in the art.
543. See In re Dillon, 919 F.2d 688 (Fed. Cir. 1990) (holding that claimed new chemical
compositions are not obvious when they exhibit unexpected new properties despite structural
similarities).
544. See Rudolf Jaenisch & Adrian Bird, Epigenetic Regulation of Gene Expression: How
the Genome Integrates Intrinsic and Environmental Signals, 33 NATURE GENETICS
SUPPLEMENT 245, 245-54 (2003)
Cells of a multicellular organism are genetically homogeneous but structurally
and functionally heterogeneous owing to the differential expression of genes.
Many of these differences in gene expression arise during development and are
subsequently retained through mitosis. Stable alterations of this kind are said to
be 'epigenetic', because they are heritable in the short term but do not involve
mutations of the DNA itself. Research over the past few years has focused on two
molecular mechanisms that mediate epigenetic phenomena: DNA methylation
and histone modifications. Here, we review advances in the understanding of the
mechanism and role of DNA methylation in biological processes. Epigenetic
effects by means of DNA methylation have an important role in development but
can also arise stochastically as animals age. Identification of proteins that
mediate these effects has provided insight into this complex process and diseases
that occur when it is perturbed. External influences on epigenetic processes are
seen in the effects of diet on long-term diseases such as cancer. Thus, epigenetic
mechanisms seem to allow an organism to respond to the environment through
changes in gene expression. The extent to which environmental effects can
provoke epigenetic responses represents an exciting area of future research.
Id.; see also Shiv I.S. Grewal & Danesh Moazed, Heterochromatin and Epigenetic Control of
Gene Expression, 301 SCIENCE 798, 798-802 (2003).
Eukaryotic DNA is organized into structurally distinct domains that regulate gene
expression and chromosome behavior. Epigenetically heritable domains of
heterochromatin control the structure and expression of large chromosome
domains and are required for proper chromosome segregation. Recent studies
have identified many of the enzymes and structural proteins that work together to
assemble heterochromatin. The assembly process appears to occur in a stepwise
manner involving sequential rounds of histone modification by silencing
complexes that spread along the chromatin fiber by self-oligomerization, as well
as by association with specifically modified histone amino-terminal tails. Finally,
an unexpected role for noncoding RNAs and RNA interference in the formation
of epigenetic chromatin domains has been uncovered.
Id.
545. See In re Dillon, 919 F.2d 688 (Fed. Cir. 1990).
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5. Enablement and Disclosure Requirement
Sections 112 of Title 35 of the United States Code requires that,
to be patentable, specifications of patents must enable any person
skilled in the art to which the patent pertains, to make and use the
claimed invention without undue experimentation. 46 In the area of
biotechnology, the enablement and disclosure requirement is met if
one skilled in the relevant art can produce and utilize the invention
without undue experimentation. 547 One way to satisfy the enabling
requirement is to deposit a sample of the subject matter of the patent
application with the USPTO, thereby guaranteeing accessibility to the
public. 5
48
It has been known that the basic scientific concepts that apply to
creating a transgenic animal and a cloned animal are virtually
identical. 549  Recently many patents were issued for transgenic
animals. 550 Based on the technical similarities between transgenic
animals and cloned animals, cloned organisms appear to be as
patentable as genetically engineered mice or pigs. 551 Additionally, if
human cloning is approved, the disclosure requirement would not
seriously restrict patentability in a majority of the cases involving
human cloning results.552
There may be challenges in determining the novelty and
nonobviousness of claims concerning cell lines isolated and
characterized by different methods and described using different
terminologies. Additionally, the scope and enforceability of these
claims comparing relatively impure cellular populations versus later,
purer populations will present a challenge.553 Issues of patentable
subject matter enter the field when claims are drawn to manipulating
546. See 35 U.S.C. § 112 (2004). Section 112 requires:
The specification shall contain a written description of the invention, and of the
manner and process of making and using it, in such full, clear, concise, and exact
terms as to enable any person skilled in the art to which it pertains, or with which
it is most nearly connected, to make and use the same, and shall set forth the best
mode contemplated by the inventor of carrying out his invention.
Id.
547. See Jagels, supra note 398, at 134.
548. See Timothy G. Hofmeyer, Comment, Everybody's Got Something to Hide Except Me
and My Patented Monkey: Patentability of Cloned Organisms, 16 J. MARSHALL J. COMPUTER &
INFo. L. 971,992 (1998).
549. See id. at 984.
550. Id.
551. Id. at993.
552. See Jagels, supra note 398, at 140-41.
553. See Woessner, supra note 461, at 843-44.
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embryonic material and ultimately regenerating embryos and even
transgenic humans.554
V. CONCLUSION
Human stem cell research is scientifically important because of
the utility of human stem cells for research, and perhaps, for patient
treatment. Currently no United States laws or regulations would
prohibit all cloning research. 555 However, human cloning and ES cell
research in the United States have been severely restricted because
federal funds may be awarded only for research on existing stem cell
lines that were derived in specified circumstances when the President
announced the policy.
556
The effective regulation of human cloning and ES cell research
requires a regulatory regime that is fully prepared to address all
scientific issues, including health risks presented by human cloning
and ES cell research. It also requires the regulatory regime to be able
to confront moral and ethical issues. The FDA regulation on human
cloning has the advantage of having a de facto regulatory regime,
making use of preexisting familiar and flexible guidelines, and
providing a preferable alternative to a broad legislative ban as
discussed earlier. However, the FDA regulation that is allegedly
limited to scientific issues would need to confront moral and ethical
issues. It is debatable whether or not the FDA's existing procedures,
that were designed long before human cloning technology was
realistically possible,557 could accommodate this new technology.
Particularly, the IND's regime does not encompass reproductive
cloning at all. 5 8 It also does not extend to any research sponsored by
private sectors.5 59
South Korea is now equipped with a framework of regulatory
measures dealing with bioethical and safety issues regarding the
application of biotechnology with its enactment of the Bioethics and
Biosafety Act in December 2003. Under the Bioethics and Biosafety
Act, a ban on human cloning is predicated on an act of implanting a
cloned embryo through SCNT technology into a woman's uterus, an
act of maintaining the implantation of a cloned embryo, or an act of
554. See id. at 844.
555. See JOHNSON & WILLIAMS, supra note 74, at CRS-3.
556. See Press Release, Office of the Press Secretary, supra note 76.
557. See Price, supra note 195, at 641.
558. Id.
559. See id.
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facilitating the birth of a cloned baby.560 The 2003 Act prescribes the
establishment of the NBRC, which will be responsible for reviewing
national policy regarding bioethics and safety, and the types, subjects,
and scope of the research utilizing excess embryos or employing
SCNT technology.56' IRBs will be responsible for reviewing the
ethical and scientific validity of biotechnology research proposals, the
proper acquisition of consent from a patient or donor, and the
measures to protect personally identifiable information.562 The
Bioethics and Biosafety Act is a relatively new area of law that must
continue to evolve with new developments in biotechnology. The key
to success of the legislation will depend upon the performance of
NBRC and IRBs in effectuating innovation, health, and humanity in
relation to human cloning and ES cell research in Korea.
The patentability of product claims derived from human cloning
and ES cell research in the United States depends upon whether the
invention is patentable subject matter and whether it does not violate
the morality doctrine. Currently, there is no statutory foundation for
excluding any invention which results from stem cell research and
human cloning based on the subject matter, with the exception of the
USPTO policy against patenting a human being based on the
Thirteenth Amendment. Ultimately, the outcome will depend upon
the definition and the scope of a human being that could be refined
only by courts or legislation.
Human cloning exposes the tension between science and
morality that challenges existing legal structures.5 63 Although the
accelerating pace of scientific discovery and advances may present an
unprecedented challenge to legislators and regulators, any attempt to
address the problem must address all the risks presented by human
cloning and ES cell research, and must consider the effect a ban
would have on beneficial technologies.
560. See The Bioethics and Biosafety Act of 2003 (South Korea), Art. 11 (2003).
561. See id.
562. Id. Art. 9.
563. See Merrill & Rose, supra note 14, at 148.
